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ABSTRACT  
 
Conventional therapy of inflammatory bowel diseases, IBD (Crohn’s disease and 
ulcerative colitis), is currently based on aminosalicylates, steroids, and 
immunosuppressants like azathioprine. Despite intensive therapy the disease may 
relapse leading to surgical bowel resections or proctocolectomy. Even though 
surgery is highly effective in terms of controlling inflammation, novel therapies based 
on accumulating knowledge of the features of IBD and gut inflammation are needed.  
 
The inflamed mucosa in IBD produces high amounts of prostaglandins and nitric 
oxide through the inducible enzymes: cyclooxygenase-2 (COX-2) and inducible nitric 
oxide synthase (iNOS), respectively. The expression and activity of these enzymes 
are associated with disease severity implicating them as potential anti-inflammatory 
drug targets. COX-2 or iNOS -related treatments in different models of IBD have 
yielded ambiguous results ranging from exacerbation of disease to abolition of 
inflammation. The purpose of the present studies was to provide additional 
information about the roles of COX-2 and iNOS in gut inflammation.  
 
Induction of COX-2 and iNOS protein and enzyme activity in acute inflammation of 
the colon was shown using a chemically-induced animal model of colitis. A 
preferential inhibitor of COX-2, nimesulide, inhibited inflammatory edema formation, 
infiltration of pro-inflammatory leukocytes and production of prostaglandin E2 by the 
inflamed mucosa. However, no beneficial effect on macroscopic disease was found 
either by treatment with preferential or unselective inhibition of the prostaglandin 
producing enzymes.  
 
Treatment of acute experimental colitis with a highly selective inhibitor of iNOS not 
only inhibited pro-inflammatory leukocyte infiltration and formation of inflammatory 
edema, but also suppressed macroscopic inflammation. This effect of selective iNOS 
inhibition was studied further in vitro in colon mucosal incubations. Expression of 
iNOS was increased in inflamed as compared with macroscopically uninflamed 
mucosa of patients with ulcerative colitis. The selective inhibitor of iNOS reduced the 
release of pro-inflammatory cytokines associated with disease activity from the 
inflamed samples.  
 
These results suggest that iNOS expression and activity in active gut inflammation 
are associated with inflammatory damage, and that selective inhibition of iNOS may 
be beneficial in treatment of colitis. Some anti-inflammatory effect may also be 
achieved by treatment with selective inhibition of COX-2, however treatment of acute 
colitis with drugs that inhibit cyclooxygenase enzymes in this study had no effect on 
macroscopic inflammation. Altogether, the role of iNOS in gut inflammation and 
related therapeutic strategies warrant further investigation. 
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ABBREVIATIONS 
 
1400W N-[3-(aminomethyl)benzyl]acetamidine 
AA arachidonic acid 
ASA acetylsalicylic acid 
5-ASA 5-aminosalicylic acid 
cAMP cyclic adenosine 3’,5’-monophosphate 
cDNA complementary deoxyribonucleic acid 
cGMP cyclic guanosine 3’,5’-monophosphate 
COX cyclooxygenase 
 COX-1 constitutive cyclooxygenase 
 COX-2 inducible cyclooxygenase 
CD Crohn’s disease 
DHA docosahexaenoic acid 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
EET epoxyeicosatrienoic acid 
ELISA enzyme linked immunosorbent assay 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GI gastrointestinal 
HETE hydroxyeicosatetraenoic acid 
HPETE hydroperoxyeicosatetraenoic acid 
IBD inflammatory bowel disease 
IFN-γ interferon-gamma  
I-kappaB inhibitor of nuclear factor kappa B 
IL  interleukin 
 IL-1, IL-6 interleukin-1, interleukin-6 
 IL-1Ra interleukin-1 receptor antagonist 
L-NAME NG-nitro-L-arginine methyl esther 
LOX lipoxygenase  
LPS lipopolysaccharide 
LT leukotriene; e.g. LTB4, leukotriene B4 
MPO myeloperoxidase 
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mRNA messenger ribonucleic acid 
NF-kappaB nuclear factor kappa B  
NO nitric oxide; NO+ nitrosonium cation; NO-, nitroxyl anion 
NOS nitric oxide synthase 
 cNOS constitutive nitric oxide synthases, includes eNOS and nNOS 
 eNOS, NOS-III endothelial nitric oxide synthase 
 iNOS, NOS-II inducible nitric oxide synthase 
 nNOS, NOS-I neuronal nitric oxide synthase 
NSAID non-steroidal anti-inflammatory drug 
ONOO- peroxynitrite anion 
PAF platelet activating factor 
PARS poly(adenosinediphosphate-ribose) synthetase 
PG prostaglandin; e.g. PGE2, prostaglandin E2 
PGEM PGE2 metabolite, 13,14-dihydro-15-keto-prostaglandin E2 
PPAR-γ peroxisome proliferator activated receptor-gamma 
RNA ribonucleic acid 
RNS reactive nitrogen species 
ROS reactive oxygen species 
RT-PCR reverse transcriptase polymerase chain reaction 
SASP salazosulfapyridine, sulfasalazine 
sGC soluble guanylate cyclase 
SNAP S-nitroso-N-acetyl-penicillamine 
TH1 T-helper cell subtype 1 
TX thromboxane; e.g.TXB2, thromboxane B2 
TNBS 2,4,6-trinitrobenzenesulfonic acid 
TNF-α tumor necrosis factor alpha 
UC  ulcerative colitis 
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1 INTRODUCTION 
 
Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic relapsing inflammatory 
bowel diseases (IBD). In UC, mucosal inflammatory lesions or ulcerations are usually 
inconsistently found in the large intestine, while in CD they may exist throughout the 
gastrointestinal tract. The lesions in UC are relatively shallow mucosal ulcerations 
while in CD they are transmural and deep. The clinical characteristics of both 
diseases include rectal bleeding, bloody stools, diarrhea, and abdominal pain. Relief 
is provided by treatment with corticosteroids, aminosalicylates or immunosuppressive 
agents. However, long-term and high-dose medical treatment for relapsing and active 
disease frequently has adverse effects. Patients may require surgical removal of the 
inflamed bowel or the whole large intestine; an operation which can provide 
considerable relief, but can also cause disability. 
 
In the inflamed mucosa in chronic IBD, the expression and activity of the inducible 
enzymes, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) are 
increased. The former produces large amounts of nitric oxide (NO) aimed at 
defensive purposes, but resulting in aggravation of inflammation through its reaction 
with superoxide in an inflammatory focus. The latter enzyme, COX-2, is a key 
enzyme in prostaglandin synthesis. Production of prostaglandin E2 (PGE2) is 
associated with increased COX-2 expression and activity. Like NO, also PGE2, has 
anti-inflammatory and pro-inflammatory properties. It inhibits infiltration of 
inflammatory cells and production of inflammatory cytokines. On the other hand, in 
inflammation PGE2 retains vasodilation and enhances vascular permeability thus 
contributing to the formation of inflammatory edema.  
 
Pharmacological inhibitors of iNOS are not yet in clinical use while selective inhibitors 
of COX-2 have recently been launched on the market. In most normal tissues, the 
expression of these inflammation-associated enzymes is hardly detectable, but is 
induced in response to proinflammatory stimuli e.g. various bacterial products and 
endogenous lymphocyte-derived activators of immune responses e.g. interleukin-1 
(IL-1) or tumor necrosis factor-α (TNF-α).  
 
Many studies so far have addressed the effects of different drugs in respect to nitric 
oxide synthase (NOS) or cyclooxygenase (COX) inhibition in experimental colitis with 
conflicting results. Regulation of excess NO or prostaglandin production has however 
been suggested to provide therapeutic benefit. In order to elaborate on the roles of 
the inducible enzymes, iNOS and COX-2 in colon inflammation the effects of 
selective inhibitors of iNOS and COX-2 were studied in an experimental model of rat 
acute colitis as well as in incubations of colon mucosal tissue samples from patients 
with UC.  
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2 REVIEW OF THE LITERATURE 
 
2.1 The inflammatory cascade 
The body’s inflammatory response is its effort to gain restitution, to reconstitute tissue 
integrity and to heal the tissue after a detrimental and destructing insult. It is aimed at 
disposing of foreign and potentially harmful material from the damaged tissue. 
According to the persistence of the stimulus, this reaction can be divided into acute 
and chronic stages, which show distinct differences, but also similarities in cellular 
activation as well as in the release of inflammatory mediators. Regardless of the 
tissue involved, the inflammatory response utilizes many analogous processes and 
mechanisms.  
 
2.1.1 Acute inflammation 
The acute inflammatory reaction is triggered by a vast array of injurious stimuli such 
as mechanical or chemical trauma, extensive heat or cold, hypoxia, nutrient 
deficiency, and microbes. This initial, innate response to an environmental challenge 
is non-specific and its course is usually similar in all vascularized tissue. 
Phagocytizing cells are attracted to the site of inflammation through activation of the 
plasma complement and kallikrein-kinin cascades, clotting system, and the release of 
cytokines (e.g. IL-8) and leukotriene B4 (LTB4) from activated, injured, or dying 
inflammatory or tissue cells (Table 1). In response to these various chemotactic 
stimuli, neutrophil granulocytes, capable of ingesting and destroying foreign material 
and bacteria, are the first to be recruited and penetrate the vascular wall from the 
systemic circulation. Local inflammatory mediators facilitate this neutrophil 
emigration, and contribute to the formation of inflammatory edema through the 
dilation and increased permeability of postcapillary venules resulting in formation of 
heat and hyperemia. Bradykinin and prostaglandins activate and sensitize tissue 
peripheral sensory nerves contributing to the generation of inflammatory pain. 
 
Upon activation the phagocytes produce high amounts of reactive oxygen and 
nitrogen species, and utilize proteolytic enzymes (e.g. elastase) and bactericidal 
agents (e.g. hypochlorous acid from myeloperoxidase) for defensive purposes, but 
nevertheless also cause host tissue damage and destruction. They aggravate the 
acute inflammatory response through the release of chemotactic substances, 
cytokines, and lipid mediators. The classic hallmarks of inflammation: reddening, 
edema, heat, pain, and loss of function are all present in acute inflammation.  
 
In order to endogenously limit the inflammatory response, tissue cells produce anti-
inflammatory agents, which can inhibit the actions of pro-inflammatory cytokines, 
proteases, and oxygen radicals. Such mediators include cytokines (IL-4, IL-10), 
cytokine antagonists (IL-1 receptor antagonist, soluble TNF-α receptor), and 
enzymes (e.g. antiproteases and superoxide dismutases).  
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The acute, innate inflammatory reaction ends favorably with its resolution, clearance 
of foreign material, and healing through regeneration or fibrosis. It may also progress 
to a more long lasting response, chronic inflammation or abscess formation. 
 
2.1.2 Chronic inflammation 
After the acute phase inflammation persists if the initial stimulus is not removed, and 
the chronic phase of inflammation ensues. Using the stage set by the acute 
response, increased infiltration and activation of lymphocytes and monocyte/ 
macrophages overcome the neutrophil granulocyte dominance of acute inflammation. 
The chronic inflammatory reaction is usually more specifically oriented against 
components of the primary insult than the acute response, and is therefore 
characterized as adaptive immunity or the “second line” of defense. This type of 
specificity relies on the clonal expansion of a specific subset of lymphocytes capable 
of recognizing the foreign antigen and eliciting a cytotoxic, an immunomodulatory, or 
an antibody secretory response.  
 
In addition to the subsiding neutrophils, immune effector functions in the chronic 
phase are elicited through the phagocytic and killing actions of macrophages, 
cytotoxic T-cells, and natural killer cells. They regulate the functions of, and their 
functions are regulated by T-helper-cells and B-cells, which secrete cytokines and 
antibodies, respectively. Activating cytokines e.g. IL-1, IL-6, or TNF-α augment many 
cell mediated immune functions while inhibitory cytokines e.g. IL-4, IL-10, or 
transforming growth factor beta suppress them. As in acute inflammation, the 
process is driven by the interaction of many mediators, but still by using the same 
effector pathways. The most favorable outcome of chronic inflammation is healing 
either through scarring or regeneration.  
 
Granulomatous inflammation is a hallmark of some chronic inflammatory processes, 
and is characterized by the presence of an aggregate of activated macrophages 
(some joint together as epithelioid giant cells) encompassed by lymphocytes. 
Granulomas are found in tuberculosis and sarcoidosis, but are a distinct feature of 
CD as well. Interestingly, unregulated cellular activation and unbalanced cytokine 
profile are implicated in e.g. UC and CD and are regarded to ultimately contribute to 
the perpetuation and chronic relapsing nature of these diseases.  
13
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2.2 Nitric oxide 
Nitric oxide (NO) is a radical, highly reactive and diffusible gas (dissolved 
nonelectrolyte in biological fluids), which is formed in the body in a number of 
different cell types through a reaction catalyzed by homodimeric, nitric oxide 
synthases (NOS) (Moncada et al., 1991; Moncada, 1992; Änggård, 1994; Schmidt 
and Walter, 1994). The reaction catalyzed by NOS (Figure 1) requires a number of 
different co-factors (Table 2) (Knowles and Moncada, 1994; Marletta et al., 1998).  
Three types of NOS have been identified, two isoforms of which are constitutive and 
calcium-dependent, and one is inducible and calcium-independent (Table 2) 
(Alderton et al., 2001). The expression of the inducible isoenzyme (inducible NOS, 
iNOS, NOS-II) is induced by bacteria-derived lipopolysaccharide, mitogenic stimuli, 
and proinflammatory cytokines (Förstermann and Kleinert, 1995; Farrell and Blake, 
1996). iNOS was originally found in activated macrophages (Table 2) (McCall et al., 
1989; Yui et al., 1991). It produces high amounts of NO, at approximately 1000 times 
the concentrations achieved by the constitutive enzymes, for immunodefensive 
purposes (Nathan, 1997; Coleman, 2001). The expression of iNOS has been found 
to be increased in sites of active inflammation in many inflammatory diseases e.g. 
inflamed synovia in rheumatoid arthritis (Stichtenoth and Frolich, 1998), and inflamed 
colon mucosa in colitis (Singer et al., 1996; Guslandi, 1998). A low level of 
physiological iNOS expression is also present in the normal (Roberts et al., 2001b) 
and uninflamed colon (Colon et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The reaction catalyzed by nitric oxide synthases. 
NO for the regulation of physiological responses is produced by consitutively 
expressed NOS enzymes found in many cell types (Table 2) (Förstermann and 
Kleinert, 1995). One of the NOS enzymes was initially found in nerve cells, thus it 
was named neuronal NOS (nNOS or NOS-I) (Garthwaite et al., 1988; Bredt et al., 
1991; Mayer and Andrew, 1998). nNOS derived NO functions as a neuronal 
messenger and serves diverse functions related to memory and neuronal signaling 
(Brenman and Bredt, 1996; Prast and Philippu, 2001). In the periphery, NO is one of 
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the transmitters released from the non-adrenergic, non-cholinergic (NANC) nerves 
(Lefebvre, 1995) and it regulates gastrointestinal (Bult et al., 1990; Sanders and 
Ward, 1992), airway (Belvisi et al., 1992) and cerebral artery (Toda and Okamura, 
1996) smooth muscle tone, and penile erection (Burnett et al., 1992). Endothelial 
NOS (eNOS or NOS-III) is a NO-producing enzyme found initially in vascular 
endothelial cells (Marsden et al., 1992; Knowles and Moncada, 1994). NO produced 
by eNOS acts as a vasodilating and antiaggregatory substance (Moncada et al., 
1991; Schmidt and Walter, 1994). A portion of NO in the body is formed by a NOS-
independent mechanism. NO is formed e.g. through the reduction of nitrite by 
bacterial nitrite reductase in the gut (Duncan et al., 1995), or in acidic conditions of 
the stomach and skin (Weitzberg and Lundberg, 1998). In vivo, preformed nitric oxide 
can be stored in and released from nitrosothiols (Hogg, 2002). 
 
 
Table 2. Some features of nitric oxide synthases. 
 
 nNOS, NOS-I  eNOS, NOS-III iNOS, NOS-II 
Molecular weight 160 kDa 130 kDa 130 kDa 
Expression Constitutive Constitutive Inducible 
Expressional control   +: LPS, IL-1, TNF-α 
-: glucocorticoids  
Expressing cells  Neurons Endothelial cells Macrophages, 
lymphocytes, epithelial 
cells, smooth muscle 
cells etc. 
NO production Picomoles Picomoles Nano- to micromoles 
Cellular localization Cytosolic Membrane associated Cytosolic 
Cofactors Calmodulin, tetrahydrobiopterin, NADPH, FAD, FMN, heme 
[Ca2+]i-activated + + - 
Post-translational 
modifications 
Homodimerisation Homodimerisation, 
Myristoylation 
Homodimerisation 
FAD, flavine-adenine dinucleotide; FMN, flavine mononucleotide; LPS, lipopolysaccharide;                
IL, interleukin; TNF-α, tumor necrosis factor alpha; NOS, nitric oxide synthase; NADPH, reduced form 
of nicotine adenine dinucleotide phosphate; [Ca2+]i, intracellular calcium 
 
 
In relation to its oxidation state, nitric oxide may exist as the nitroxyl anion (NO-), NO, 
or the nitrosonium cation (NO+) (Gow and Ischiropoulos, 2001). Due to this chemical 
variability, it has been suggested that the NOS enzymes should therefore be called 
nitrogen oxide synthases (Alderton et al., 2001). The nitrosonium character of NO is 
thought to be responsible for nitrosothiol formation and subsequent modifications in 
the activity of ion channels, enzymes, G-proteins, or neuronal N-methyl-D-aspartate 
receptors (Broillet, 1999). The reactions of NO- have not yet been clearly dissected 
and defined. However, the cytotoxic effects of the NO- -donor, Angeli’s salt may help 
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clarify some aspects of this putatively detrimental side of NO-biochemistry (Colton et 
al., 2001; Miranda et al., 2001). For the sake of clarity, if not otherwise stated, the 
term NO is used throughout the text for all these molecular species. 
 
The effects of NO can be divided into either direct or indirect forms (Table 3), and are 
associated with low or high NO-concentrations, respectively (Broillet, 1999; Davis et 
al., 2001). The principal actions of NO are mediated by its binding to the heme-
moiety of the soluble guanylate cyclase (sGC) leading to enzyme activation and the 
subsequent increase in intracellular cyclic guanosine 3’,5’-monophosphate (cGMP) 
concentrations (Katsuki et al., 1977; Hobbs, 1997; Lucas et al., 2000). cGMP is a 
second messenger of NO functions and regulates the activity of cGMP-dependent 
protein kinases, cGMP-gated ion channels, and phosphodiesterases (Biel et al., 
1998; Smolenski et al., 1998; Lucas et al., 2000). In addition to activating sGC, NO 
may affect the functions of other heme containing enzymes such as cyclooxygenases 
(Salvemini et al., 1993) or mitochondrial aconitases (Gardner et al., 1997). NO has 
also been shown to have direct effects on ion-channels (Volk et al., 1997; Janssen et 
al., 2000). Indirect effects of NO are mediated through the formation of reactive 
nitrogen species (RNS) (Davis et al., 2001). Oxidation of NO results in formation of 
RNS either through auto-oxidation (reaction with molecular oxygen) or through the 
reaction with superoxide (Hughes, 1999).  
 
 
Table 3. Effects of nitric oxide at the cellular level. 
 
Direct effects mediated by NO in low NO concentrations 
- Reactions with Fe- proteins e.g. hemeproteins (guanylate cyclase) 
- Reactions with Zn- proteins e.g. Zn-finger proteins (p53) 
- Formation of nitrotyrosine with tyrosyl radicals 
- Anti-oxidative effects through reactions with e.g. lipid peroxides 
- Nitrosothiol formation, S-nitrosylation 
 
Indirect effects, mediated by NO metabolites at high NO concentrations 
- N2O3 (derived from NO auto-oxidation) mediated DNA deamination and nitrosylation 
(nitrosothiol, nitrosamine formation) e.g. nitrosylation of cysteine residues 
- Peroxynitrite (derived from the reaction with superoxide) mediated: 
 
- protein nitration (formation of nitrotyrosine) 
- lipid oxidation and nitration 
- DNA oxidation and nitration, DNA strand breaks 
- irreversible inhibition of mitochondrial respiration 
 
NO, nitric oxide 
In inflammation, excessively high concentrations of NO are produced by iNOS for 
mainly defensive purposes (Nathan, 1997). For example, in an experimental model of 
colitis iNOS deficient mice showed an increased inflammatory response and delayed 
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healing when subjected to colitis induction suggesting that iNOS has anti-
inflammatory activity and is important in resolving inflammation (McCafferty et al., 
1999). However, a dualistic role of iNOS-derived NO in inflammation presents itself 
through NO-metabolism. Under oxidative stress, NO rapidly reacts with superoxide 
(O2-) to produce the toxic, oxidizing and nitrosating peroxynitrite anion (ONOO-) 
(Koppenol et al., 1992; Beckman and Koppenol, 1996). The reaction between NO 
and O2- occurs more rapidly than the neutralization of superoxide through superoxide 
dismutases (Pryor and Squadrito, 1995). It has been shown that iNOS may produce 
O2- instead of NO when depleted of substrates or co-factors e.g. L-arginine or 
tetrahydrobiopterin (Xia et al., 1998; Vasquez-Vivar and Kalyanaraman, 2000), and 
thereby directly contribute to oxidative state. Peroxynitrite is highly toxic and causes 
mutations in DNA (Epe et al., 1996; Szabo et al., 1996; Burney et al., 1999), 
disruptions in mitochondrial function and respiration (Castro et al., 1994; Sharpe and 
Cooper, 1998; Brown, 1999; Bringold et al., 2000), and modulations in protein thiol, 
tyrosine and prosthetic groups (Beckman and Koppenol, 1996; Bouton, 1999). The 
role of peroxynitrite is further complicated by the fact that it also has other functions 
including being an antimicrobial agent (Xia and Zweier, 1997; Akaike and Maeda, 
2000). 
 
NO has a clearly defined physiological mechanism of action. It binds to its 
intracellular receptor, sGC leading to stimulation of cGMP production. Beyond this, 
NO has complex diverse functions related to its local concentrations and metabolism 
(Table 3). Even at high concentrations NO has anti-oxidative, anti-microbial, and anti-
viral effects that benefit the host. However, the production of NO through iNOS and of 
O2- in an inflammatory focus result in increased formation of peroxynitrite and RNS, 
which are considered detrimental. Moreover, nitrosylation of amines by RNS may 
yield potent mutagens and carcinogens (Jaiswal et al., 2001). 
 
2.2.1 Nitric oxide synthase inhibitors  
The increased production and the detrimental metabolism of NO in inflammation, and 
the fact that iNOS is almost exclusively expressed in inflamed tissue provide the 
basis for development of iNOS inhibitors as anti-inflammatory drugs. Inhibition of 
NOS is achieved through either a mechanism-based, or a cofactor inhibiting or 
antagonizing manner (Bryk and Wolff, 1999; Hobbs et al., 1999; Alderton et al., 
2001). Some of the most used mechanism-based NOS inhibitors are shown in Table 
4. Due to similarities in reaction mechanisms between constitutive and inducible 
NOS, selective inhibition of iNOS has been difficult to achieve. The majority of NOS-
inhibitors are substrate analogs i.e. their inhibitory action on NOS can be 
antagonized with high concentrations of L-arginine (Bryk and Wolff, 1999). One of the 
oldest NOS-inhibitors is NG-nitro-L-arginine (L-NNA), which shows selectivity for the 
constitutive enzymes, particularly for nNOS over eNOS and iNOS in many 
experimental models (Alderton et al., 2001). L-NNA produces a competitive 
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irreversible inhibition of both eNOS and nNOS, and is a competitive reversible 
inhibitor of iNOS (Dwyer et al., 1991; Moore and Handy, 1997). The L-arginine 
analog, NG-nitro-L-arginine methyl esther (L-NAME) is a more soluble derivative of  
L-NNA. L-NAME is hydrolyzed by cellular esterases to form L-NNA (Pfeiffer et al., 
1996). In addition to L-NNA and L-NAME many non-selective inhibitors of NOS have 
been identified. These include the arginine analog NG-methyl-L-arginine (L-NMA,     
L-NMMA), and the heme-binding thiocitrulline derivatives L-thiocitrulline (L-TC) and 
S-alkyl-L-thiocitrulline (Mayer and Andrew, 1998). Treatment with non- or cNOS-
selective NOS-inhibitors results in increased vascular smooth muscle tone and blood 
pressure (Aisaka et al., 1989; Rees et al., 1989), an effect not seen with selective 
iNOS inhibitors (Garvey et al., 1997). 
 
Recently, a novel highly selective inhibitor of iNOS, N-[3-(aminomethyl)benzyl]-
acetamidine (1400W), has become available (Garvey et al., 1997). The non-amino 
acid structured 1400W has been shown to inhibit iNOS at 50-5000 times lower 
concentrations than cNOS (Garvey et al., 1997; Alderton et al., 2001). 1400W is an 
irreversible, or slowly reversible inhibitor of iNOS whereas its inhibitory effect on the 
constitutive isoforms is more readily reversible (Garvey et al., 1997). Since selective 
iNOS inhibition is considered a promising field of drug research novel compounds 
(e.g. isoquinolinamine and thienopyridine -derivatives) are constantly developed 
(Beaton et al., 2001a; Beaton et al., 2001b).  
 
Other NOS-inhibitors with varying selectivity for iNOS over the constitutive enzymes 
include aminoguanidine, L-NG-(1-iminoethyl)lysine (L-NIL), and L-NG-(1-iminoethyl)-
ornithine (L-NIO) (Mayer and Andrew, 1998; Bryk and Wolff, 1999). Aminoguanidine 
for example is also an inhibitor of diamine oxidase (Kusche et al., 1987) and an 
antioxidant (Yildiz et al., 1998). These NOS-unrelated effects may complicate 
interpretation of experimental results when using NOS-inhibitors in experiments 
(Zhou et al., 2002). 
 
 
Table 4. Some of the experimentally most used nitric oxide synthase inhibitors and 
their isoform selectivities. Adapted from Alderton et al. (2001). 
 
1400W, N-[3-(aminomethyl)benzyl]acetamidine; L-NNA, NG-nitro-L-arginine; L-NMMA, NG-methyl-L-
arginine; L-NIL, L-NG-(1-iminoethyl)-lysine; L-NIO, L-NG-(1-iminoethyl)-ornithine 
 
 Selectivity (fold) 
 iNOS vs. nNOS iNOS vs. eNOS nNOS vs. eNOS 
L-NNA 0.09 0.11 1.2 
L-NMMA 0.7 0.5 0.7 
L-NIL, L-NIO 20 30-50 1.3 
1400W 32 >4000 >130 
Aminoguanidine 5.5 11 1.9 
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2.3 Eicosanoids 
The 20 carbon backboned fatty acid, arachidonid acid (AA; 5,8,11,14-
eicosatetraenoic acid), is a crucial component of the eucaryotic cell membrane. It 
resides estherized in membrane phospholipids, preferably in phosphatidylcholine or 
phosphatidylethanolamine. Unesterified, free AA is cleaved from these structures by 
the actions of phospholipases, mainly by phospholipase A2 (PLA2). When released 
intracellularly, AA is a substrate in the synthesis of a wide spectrum of cellular lipid 
mediators (Brash, 2001).  
 
2.3.1 Prostanoids 
It was found in the 1970s that large amounts of primary prostanoids, prostaglandin D2 
(PGD2), PGE2, PGF2α, PGI2, and thromboxane A2 (TXA2) are present and produced 
in inflammation (Moncada et al., 1973; Velo et al., 1973), and that their production is 
inhibited by treatment with acetylsalicylic acid –like anti-inflammatory drugs (Collier 
and Flower, 1971; Vane, 1971; Smith and Willis, 1971).  
 
Prostanoids have many modulatory functions in the inflammation process (Tilley et 
al., 2001). The main E-series prostaglandin, PGE2, for example has hyperalgesic 
effects (Ferreira et al., 1978; Stock et al., 2001) and it is involved in the generation of 
fever (Aronoff and Neilson, 2001). However, PGE2 also has anti-inflammatory effects: 
it inhibits leukocyte and lymphocyte functions in inflammation (Wheeldon and Vardey, 
1993; Kaur et al., 1999; Hori et al., 2000; Nataraj et al., 2001).  
 
Prostaglandins are formed from their primary substrate, arachidonic acid (Figure 2). 
Under certain conditions, other fatty acids such as eicosapentaenoic acid or dihomo-
gamma-linolenate can also be utilizied as substrates by the prostaglandin 
synthesizing cyclooxygenase (COX) enzymes as well. Endogenous arachidonic acid 
is stored in plasma membranes in phospholipids, and is enzymatically released by 
the actions of different phopholipases (PL), mainly by PLA2. Free AA is then 
converted to PGG2 and PGH2 by the COX (also known as prostaglandin 
endoperoxide H synthase) -enzymes (Figure 2).  
 
To date, two isoforms of COX have been identified (Table 5) (Vane et al., 1998). 
These enzymes use identical processes in the catalysis of PGH2, which is then 
further metabolized either by enzymatic or non-enzymatic pathways into different 
prostanoids (Smith et al., 1996; Smith et al., 2000). The constitutive isoform of COX, 
COX-1, is constantly expressed in most tissues under physiological conditions.  
COX-1 –derived prostaglandins are most important in the regulation of arterial tone, 
platelet aggregation, mucosal integrity of the gastrointestinal tract, and perfusion 
maintenance in the kidneys (Eberhart and DuBois, 1995; DuBois et al., 1998; Vane 
et al., 1998). The expression of the inducible isoform, COX-2, is increased in 
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response to pro-inflammatory stimuli e.g. IL-1, TNF-α, IL-6, and bacterial 
lipopolysaccharide (LPS) (Jones et al., 1993; Wu, 1996; Mitchell and Warner, 1999).  
 
Some degree of constitutive COX-2 expression is, however, normally present in 
different tissues (Vane et al., 1998). Of utmost importance in this respect are the 
kidneys, the central nervous system, and the female reproductive organs. At these 
sites, COX-2 activity and prostaglandin production is required for homeostatic and 
physiological processes (DuBois et al., 1998; Funk, 2001; Hinz and Brune, 2002). 
 
 
Table 5. Some features of cyclooxygenases. 
 
 COX-1 COX-2 
 
Molecular weight 
 
72 kDa 
 
72 or 74 kDa 
 
Expression 
 
Constitutive 
 
Inducible 
 
Expressional control 
 
- 
 
+:LPS, IL-1, TNF-α 
-: Glucocorticoids 
 
Expressing cells 
 
Ubiquitous 
 
Ubiquitous (macrophages, smooth 
muscle cells, fibroblasts, epithelial 
cells, etc.) 
 
Cellular localization 
 
Endoplasmic reticulum 
 
Endoplasmic reticulum, nuclear 
envelope 
 
Cofactors 
 
Heme, glycosylation required for optimal activity 
 
[Ca2+]i –activated 
 
Yes 
 
Yes 
 
Post-translational 
modifications 
 
Homodimerisation, N-
glycosylation 
 
Homodimerisation, N-glycosy-
lation (72kDa species 3 groups, 74 
kDa species 4 groups) 
 
Substrate specificity 
 
Narrow (AA, dihomo-γ-
linoleate) 
 
Wide due to larger catalytic cleft 
(AA, dihomo-γ-linoleate, α-lino-
lenate, eicosapentaenoic acid) 
AA, arachidonic acid; IL-1, interleukin-1; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor 
alpha;[Ca2+]i, intracellular calcium 
 
During the first stages of inflammation prostanoids are produced via the constitutive 
COX-1 activity in response to increased substrate availability due to the activation of 
phopholipases (Smith et al., 2000). Induction of COX-2 expression requires new 
protein synthesis and thus time, and is a more delayed process (Wu, 1996). Later on, 
the increased COX-2 activity is the principal contributor to the production of 
inflammatory prostanoids (DuBois et al., 1998; Herschman, 1999). It has been 
suggested, that increased COX-activity and PGH2 production saturates the 
isomerase-derived primary prostanoid formation and leads to non-enzymatic 
production of PGI2 and PGE2, the major inflammatory prostaglandins (Brock et al., 
1999; Mitchell and Warner, 1999). Also the expression of the PGE2 synthetizing 
enzyme (PGE-synthase) has been found to be inducible (Jakobsson et al., 1999).  
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The effects of prostaglandins are mediated through stimulation of their respective 
receptors (Table 6). For example, stimulation of PGE2-receptors EP2 or EP4 results in 
increase of intracellular cyclic adenosine monophosphate (cAMP) and subsequent 
relaxation of smooth muscle. EP2 activation is also associated with anti-inflammatory 
effects of PGE2 such as the inhibition of leukocyte activation. EP3 stimulation is 
mediated by a decrease in intracellular cAMP concentrations, and is associated with 
inhibition of acid secretion from gastric parietal cells. (Narumiya et al., 1999) 
 
Through stimulation of their receptors the prostanoids mediate and regulate many 
physiological functions in the gastrointestinal tract (Whittle and Vane, 1987; Eberhart 
and DuBois, 1995). They inhibit gastric acid secretion, increase the secretion of 
protective mucus, blood flow, and modulate intestinal motility (Eberhart and DuBois, 
1995). 
 
 
Table 6. Prostaglandin receptors, signal transduction and tissue distribution. Adapted 
from Narumiya et al. (1999). 
 
Receptor 
type 
Subtype Second 
messenger 
Tissue distribution 
DP  cAMP ↑ Brain, meninges, intestine 
EP EP1 Ca2+ Kidney, lung, intestine 
 
EP2 cAMP ↑ Uterus 
 
EP3 cAMP ↑/↓/PI *) Kidney tubuli, brain, smooth muscle, 
intestine, enteric ganglia 
 
EP4 cAMP ↑ Kidney glomeruli, intestine 
FP  PI Corpus luteum, kidney, heart, lung, intestine 
IP  cAMP ↑/ PI Platelets, smooth muscle 
TP TPα PI/cAMP ↓ Lung, kidney, heart, thymus, spleen 
 TPβ PI/cAMP ↑ Lung, kidney, heart, thymus, spleen 
↑/↓, increase/decrease; cAMP, cyclic adenosine-3’,5’-monophosphate; DP, prostaglandin D2 receptor; 
EP, prostaglandin E2 receptor; FP, prostaglandin F2 receptor; IP, prostaglandin I2 receptor; TP, 
thromboxane receptor; PI, phosphoinositol cascade. *) isoform (e.g. EP3A-D) specific action  
 
2.3.2 Other arachidonic acid derivatives 
In addition to COX-enzymes, arachidonic acid is metabolized by different 
lipoxygenases (LOX) to form leukotrienes, hydroxyeicosatetraenoic acids (HETEs), 
hydroperoxyeicosatetraenoic acids (HPETEs), lipoxins, hepoxilins, and oxylipins, and 
by cytochrome P450 epoxygenases to form epoxyeicosatrienoic acids (EETs), 
HETEs and diHETEs (Eberhart and DuBois, 1995; Brash, 1999; Zeldin, 2001). 
Except for the 5-lipoxygenase (5-LOX) -derived leukotrienes (Funk, 2001), the roles 
and functions of these other lipid mediators have been less intensively studied, but 
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there is emerging interest in their mechanisms of action in different physiological and 
pathophysiological states (Levy et al., 2001). 
 
The 5-LOX enzymes catalyze oxygenation of position 5 in AA and the formation of 
leukotriene A4 (LTA4) (Brash, 1999). LTA4 may undergo subsequent enzymatic 
conversion to LTB4 by LTA4 hydrolase or to the cysteinyl leukotriene (LTC4, LTD4, 
and LTE4) precursor LTC4 by LTC4 synthase (Funk, 2001).  
 
The granulocytes, mast cells and macrophages express 5-LOX and possess 
leukotriene synthesis capacity far greater than parenchymal or matrix cells (Peters-
Golden, 1998; Funk, 2001). However, LTA4 secreted by macrophages or neutrophils 
can be converted by parenchymal cells to these downstream metabolites (Feinmark 
and Cannon, 1986; Peters-Golden, 1998). LTB4 is a potent chemotactic activator of 
neutrophil granulocytes and macrophages in inflammation (Yokomizo et al., 2001), 
while the cysteinyl leukotrienes increase vascular permeability and induce smooth 
muscle contraction (Busse, 1998; Sala and Folco, 2001). 
 
2.3.3 Cyclooxygenase inhibitors 
For centuries it has been known to man that fever can be suppressed by ingesting an 
extract from willow bark, which since has been shown to contain high amounts of 
salicylates. In 1971, it was shown that the mechanism of action of salicylates and 
other non-steroidal anti-inflammatory drugs (NSAIDs) is their inhibitory action on the 
prostaglandin producing COX-enzyme. Twenty years later it became evident that 
there are two COX enzymes, COX-1 and -2, and drugs with selectivity towards the 
former are associated with increased adverse effects, mainly gastrointestinal 
ulcerations (Hawkey, 1999; Laine et al., 1999; Warner et al., 1999). Since the 
discovery of the inflammation induced COX-2 in 1991 (Xie et al., 1991) and the 
structure of its gene in 1994 (Appleby et al., 1994), there has been an ever-
increasing tendency to produce anti-inflammatory drugs that selectively inhibit this 
inflammation-associated enzyme. The rationale is to produce anti-inflammatory drugs 
that are targeted to the site of inflammation, suppress a process detrimental to the 
host while sparing the physiological functions of prostanoids. Recently, after the 
report that treatment with a selective COX-1 inhibitor (SC-560) was not associated 
with gastrointestinal damage (Wallace et al., 2000) it was proposed that non-selective 
inhibition of both COX-enzymes is required for gastric ulceronigenic toxicity. A 
selection of anti-inflammatory drugs and their isoform selectivities is shown in     
Table 7. 
 
Acetylsalicylic acid (aspirin, ASA) is the oldest commercial NSAID; it was launched in 
1899 (Vane, 2000). Its mode of action is, however, different from the other NSAIDs. 
ASA covalently and irreversibly acetylates the COX-enzyme at a key position for 
substrate entry into the enzyme’s catalytically active site. Acetylation of the amino 
acid serine at position 530 or 516 by ASA results in loss of PGH2 synthesizing activity 
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of the COX-1 and COX-2 enzymes, respectively (Ferreira et al., 1971; Roth et al., 
1975; Mancini et al., 1994; Marnett et al., 1999). Thus, synthesis of prostaglandins 
from AA is suppressed by treatment with ASA. Due to the relatively fast de novo 
protein synthesis of COX-2, and low turnover of the constitutive COX-1, the inhibitory 
effect of ASA on COX-1 is pronounced. ASA-acetylated COX-2 produces 15-(R)-
hydroxyeicosatetraenoic acid (15-HETE) instead of PGH2 from AA, and functions 
principally as a 15-lipoxygenase (Mancini et al., 1994). Furthermore, 15-HETE is 
metabolised by the 5-LOX –enzymes into lipoxins, which have been suggested to 
have anti-inflammatory activities (Samuelsson et al., 1987). It is also interesting to 
note that in the search for more and more COX-2 selective anti-inflammatory drugs 
even aspirin-like molecules, which covalently, irreversibly, and preferentially 
inactivate COX-2 have been developed (Kalgutkar et al., 1998). 
 
 
Table 7. Some inhibitors of cyclooxygenases and their isoform selectivities adapted 
from Warner et al. (1999). 
 
 Selectivity (fold) COX-1 vs. COX-2  
 
 
IC50 -ratio 
(COX-2/COX-1) 
IC80  -ratio 
(COX-2/COX-1) 
IC50 µM 
(COX-2) 
Non-selective    
Acetylsalicylic acid >100 >100 >100 
Ketoprofen 61 22 2.9 
Indomethacin 80 11 1.0 
Ibuprofen 0.9 1.2 7.2 
 
Selectivity for COX-2    
Celecoxib 0.7 0.21 0.83 
Nimesulide 0.19 0.17 1.9 
NS398 0.051 0.015 0.35 
L745,337 <0.01 <0.01 8.6 
Rofecoxib 0.013 <0.05 0.84 
IC50/IC80, concentration causing 50/80% of maximal inhibition 
 
Indomethacin is a widely used, potent, non-selective, and slowly reversible inhibitor 
of both COX-1 and COX-2 (Stanford et al., 1977; Mitchell et al., 1993). Like aspirin 
and other non-selective NSAIDs, treatment with indomethacin is associated with 
gastrointestinal bleeding and ulcerations (Warner et al., 1999). It has been proposed 
that a part of indomethacin’s adverse effect is unrelated to COX-inhibition, and that 
the ulcerogenic activity is associated with the combined disruptive action of 
indomethacin and bile on the mucosal barrier (Yamada et al., 1993; Lichtenberger, 
2001). Indomethacin has been shown to have anti-inflammatory radical scavenging 
properties in vitro (Prasad and Laxdal, 1994).  
 
Nimesulide preferentially inhibits COX-2 over COX-1 in clinically used concentrations 
(Warner et al., 1999). Nimesulide is a sulphonamide derivative, and has additional 
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mechanisms of action besides COX-inhibition (Singla et al., 2000). For example, 
nimesulide is a steroid receptor agonist (Pelletier et al., 1999), inhibits leukocyte 
functions and chemotaxis (Dallegri et al., 1992; Dallegri et al., 1995), inhibits the 
activity of complement (Auteri et al., 1988), and functions as an antioxidant (Facino et 
al., 1993). In accordance with the hypothesis on gastroduodenal toxicity and COX-
unselectivity is the fact that treatment with nimesulide is associated with less 
gastroduodenal lesions as compared to non-selective COX-inhibitors (Warner et al., 
1999; Shah et al., 2001). 
 
A novel group of NSAIDs are the COX-2 selective coxibs, rofecoxib and celecoxib 
(Turini and DuBois, 2002). They are associated with good anti-inflammatory potential 
and low risk of gastroduodenal side effects (Warner et al., 1999). However, similar to 
other NSAIDs they inhibit COX-2 activity and production of prostanoids relevant for 
perfusion maintenance in the kidney and cause fluid retention (Harris and Breyer, 
2001).  
 
2.4 Inflammatory bowel diseases 
Inflammatory bowel diseases are chronic relapsing diseases of the gastrointestinal 
tract characterized by bowel wall inflammation, ulcerations, diarrhea, bloody stools, 
and abdominal pain (Fiocchi, 1998; Ghosh et al., 2000; Hendrickson et al., 2002). 
The incidence of IBD is higher (4-10 per 10,000) in westernized countries than in 
developing countries or in the East (Karlinger et al., 2000; Hendrickson et al., 2002). 
IBD is divided into two separate entities: Crohn’s disease (CD) and ulcerative colitis 
(UC), both of which have distinct differences as explained in detail below and in 
Table 8. Diagnosis of IBD is based on clinical, endoscopic and histopathological 
findings. In some cases it may be almost impossible to separate the two disease 
entities. 
 
No single etiological factor or triggering agent has been identified to cause IBD, thus 
they are designated as idiopathic diseases. Many factors such as genes and 
hereditary susceptibility, environmental factors (bacteria, nutrition), and host immune 
responses have been found to play a role in the pathogenesis of IBD (Fiocchi, 1998). 
The inflamed colon mucosa in IBD does harbor more bacteria than normal mucosa 
(Schultsz et al., 1999; Swidsinski et al., 2002) even though defensive responses 
(production of pro-inflammatory cytokines and other inflammatory mediators, 
increased proliferation etc.) of the inflamed bowel wall to bacterial agents and 
cytokines are enhanced (Schreiber et al., 1998). Loss of tolerance to normal luminal 
contents has been implicated in the pathogenesis of IBD (Nagler-Anderson, 2001). 
This abnormal host response to bacteria leads to increased permeability, breakdown 
of the epithelial barrier function and subsequent potentiation of immune responses 
due to unregulated bacterial translocation in the gut (Linskens et al., 2001). The 
factors predisposing to this disadvantageous activity of the intestinal mucosa in IBD 
may include hereditary defects in distinct cellular or humoral responses (Hendrickson 
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et al., 2002). In both forms of IBD, however, end-point mediators of inflammation are 
in common. 
 
Dysregulation of host immune reactions, as well as pathological activation of the 
immune and non-immune systems are acknowledged as possible etiological or at 
least contributing factors to the perpetuated inflammatory response (Fiocchi, 1998). 
As pointed out previously, several pathways normally utilized in immune defense 
converge to promote intestinal inflammation in IBD. These contributing factors 
include cytokines, growth factors, eicosanoids, neuropeptides, reactive oxygen 
species, nitric oxide, proteolytic enzymes, antibodies, and autoantibodies (Fiocchi, 
1998). 
 
 
Table 8. Some differences between Crohn’s disease and ulcerative colitis. Adapted 
from Fiocchi (1998), Ghosh et al. (2000), and Hendrickson et al. (2002).  
 
 Crohn’s disease Ulcerative colitis  
Location of lesions Can occur throughout the GI-
tract, “skip” lesions 
Colonic involvement 
 
Rectal involvement 
 
Infrequent 
 
Frequent 
 
Perianal disease and 
fistulas 
 
Frequent 
 
Rare 
 
Lesions 
 
Transmural 
 
Limited to mucosa and 
submucosa 
 
Immunological activation 
 
TH1 subtype dominant 
 
TH2 subtype dominant 
 
Cytokine profile 
 
TNF-α, IFN-γ, IL-1, TH1-profile 
 
IL-4, IL-5, IL-6, TH2-profile 
 
Humoral 
 
Increase in IgG2 
 
Increase in IgG1, ANCA-
associated 
 
Cell mediated  
 
+, T-cell infiltration 
 
+, neutrophil infiltration 
 
Environmental factors 
 
Smoking harmful 
 
Smoking beneficial  
 
Genetic factors 
 
Partly different between UC and CD, 
familial aggregation in both 
ANCA, anti-neutrophil cytoplasmic antibodies; GI-tract, gastrointestinal tract; IFN-γ, interferon- gamma; 
IgG, immunoglobulin G; IL-1, interleukin-1; TH1, T-helper subtype 1 -cells; TNF-α, tumor necrosis 
factor alpha 
 
2.4.1 Nitric oxide  
The initial finding of increased nitrite in rectal dialysates from patients with active UC 
was published in 1986 (Roediger et al., 1986). Increased production of NO in IBD 
was then reported in 1993, and was measured as increased nitrite and nitrate 
concentrations in plasma and increased NOS-activity in inflamed colon mucosa of 
IBD patients (Boughton-Smith et al., 1993a; Boughton-Smith et al., 1993b; Guslandi, 
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1993; Middleton et al., 1993; Tran et al., 1993). This was followed by the finding that 
colon luminal gas in UC contained increased NO-concentrations (Lundberg et al., 
1994). It is now known that to a great extent the induction of iNOS activity is 
responsible for this excessive NO production in the inflamed gut (Ribbons et al., 
1995; Singer et al., 1996). In inflammation the mucosal NO-production is 1000-
10,000 times greater than the normal, physiological NO production (Lundberg et al., 
1994); the inflammatory concentrations of NO range from nanomolar to micromolar. 
Increased production of NO is not specific for IBD. Rather, it is an unspecific 
inflammatory response triggered and sustained by injury, cytokines, and microbial 
exposure (Kroncke et al., 1998). In colitis, iNOS has been localized to the epithelium 
(Godkin et al., 1996; Singer et al., 1996; Dijkstra et al., 1998), to infiltrated or resident 
cells of the lamina propria (Kimura et al., 1998), and to fibroblasts (Ikeda et al., 1997). 
The expression of iNOS was localized to smooth muscle cells and to the muscular 
layer, when colitis was associated with toxic dilatation of the colon (Mourelle et al., 
1995). It has also been shown that the pattern of iNOS expression may vary 
according to the stage of inflammation (Vento et al., 2001). In UC, iNOS activity and 
expression are quite strictly associated with active inflammation (Kimura et al., 1997; 
Rachmilewitz et al., 1998), in CD this association is less clear (Tran et al., 1993; 
Kimura et al., 1997). Increased iNOS is found in the cells of inflamed areas together 
with 3-nitrotyrosine staining suggestive of increased nitrosative stress, RNS and 
peroxynitrite formation (Singer et al., 1996; Dijkstra et al., 1998; Kimura et al., 1998).  
 
One of the many features of IBD is reduced apoptosis of T-cells (Bu et al., 2001) and 
increased apoptosis of epithelial cells (Strater et al., 1997) of the intestinal mucosa. 
NO is a modulator of apoptosis (Chung et al., 2001). As for many other NO-regulated 
processes also the effects on apoptosis are dose dependent. In low concentrations 
NO inhibits apoptosis, but increases it at high concentrations supposedly through 
formation of peroxynitrite (Kim et al., 1999). A pathologic feature of the T-cells in CD 
mucosa is their resistance to NO-induced apoptosis (Ina et al., 1999). This lack of 
response may reflect some pathognomonic, supposedly of genetic origin, feature of 
CD. 
 
Evidence has accumulated which shows that iNOS-derived massive NO production 
and especially its oxidative metabolism in colitis are detrimental to the host (Guslandi, 
1998; McCafferty, 2000). The beneficial effects of NO-supplementation were 
challenged in a recent clinical trial with enteric release glyceryl trinitrate treatment in 
CD. In that study no advantageous effects were found on the clinical parameters after 
a 12-week treatment (Hawkes et al., 2001). However, even though the increased NO 
concentrations may initially have served an antimicrobial, anti-inflammatory, or 
homeostatic purpose (Kubes and McCafferty, 2000) it seems feasible to assume that 
there is lack of appropriate control in the chronically inflamed tissue for suppressing 
the undesired effects of NO (Whittle, 1997).  
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2.4.2 Eicosanoids 
Increased production of prostaglandins was implicated in the pathogenesis of IBD, 
especially UC, as early as 1975 (Gould, 1975; Gould et al., 1977; Whittle and Vane, 
1987). It was found that disease activity correlated well with the production of PGE2 
from the mucosa (Smith et al., 1979), however attempts to treat colitis with the 
NSAID, flurbiprofen, failed (Rampton and Sladen, 1981a); even disease relapses 
were seen during treatment (Rampton and Sladen, 1981b). This led the investigators 
to conclude that NSAID-therapy was of little or no benefit in UC, and that 
prostaglandins possibly had a protective role in colon inflammation. However, also 
treatment with prostaglandin analogs produced either relapses or severe diarrhea 
(Goldin and Rachmilewitz, 1983; Faich et al., 1991). A role for increased leukotriene 
synthesis in the pathogenesis of UC was then suggested (Boughton-Smith et al., 
1983), and a selective 5-LOX inhibitor was tested in UC-patients with initial promising 
results (Laursen et al., 1990). In a clinical trial thereafter, selective 5-LOX inhibition 
was found to be no better than placebo for treating patients with UC (Hawkey et al., 
1997). Similarly, increased concentrations of thromboxanes in UC and CD inspired 
further studies (Ligumsky et al., 1981; Hawkey et al., 1983), and the effects of a 
combined thromboxane receptor antagonist and inhibitor of thromboxane synthase, 
ridogrel, were beneficial in experimental models and pilot studies (Tozaki et al., 1999; 
Carty et al., 2000). However, no difference in efficacy when compared with placebo 
was found in clinical trials (Carty et al., 2001; Tytgat et al., 2002). 
 
Since the characterization of the inducible COX in 1991 (see 2.3.1), it is now 
hypothesized that in the gastrointestinal tract prostaglandins are produced for 
physiological purposes by constitutive COX-1 activity, and the COX-2 activity and 
expression is induced in inflammation. Induction of COX-2 in IBD has been mainly 
localized into inflamed mucosa and particularly to epithelial and immune cells 
(Hendel and Nielsen, 1997; Singer et al., 1998). Activated eosinophils and 
macrophages (Raab et al., 1995) as well as myenteric neurons (Roberts et al., 
2001a) also contribute to the production of prostaglandins in colitis. Recently, in 
contrast to these findings COX-1 expressing mononuclear cells in the lamina propria 
were identified as the major source of prostaglandins in inflamed mucosa. Their 
amount exceeded the COX-2 positive cells twofold even during active inflammation 
(Cosme et al., 2000). 
 
In addition to increased production of prostanoids, elevated concentrations of 15-
HETE have also been measured in both the mucus and mucosa in UC (Zijlstra and 
Wilson, 1991; Zijlstra et al., 1992). In an experimental colitis model 15-HETE was 
shown to possess mild anti-inflammatory activity (van Dijk et al., 1993). There is also 
some data from clinical trials on the beneficial efficacy of polyunsaturated fatty acid 
supplementation, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) in IBD (Grimminger et al., 1993; Shoda et al., 1995; Almallah et al., 2000a; 
Almallah et al., 2000b). 
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The role of COX-2 and eicosanoids in gut inflammation is complex, and the 
hypothesis of beneficial COX-1 activity and detrimental COX-2 activity seems 
oversimplified. Moreover, as chronic inflammation is a premalignant state, and 
NSAID treatment has preventive chemotherapeutic effects on colon cancer and 
premalignant states, COX-2 selective inhibitors may prove to be effective in retarding 
malignant change in inflammation associated tumorigenesis. 
 
2.4.3 Pro-inflammatory cytokines 
According to the widely accepted hypothesis on IBD pathology, there are different 
cytokine profiles for UC and CD (MacDonald et al., 2000). They are characterized by 
activation of distinct T-helper cell subtypes. For CD there is evidence of a TH1 cell 
predominance associated with the production of IFN-γ and TNF-α (Romagnani et al., 
1997) (Table 9). In UC, there is not so strong experimental evidence of a      T-cell 
dominance even though TH2 cells and associated cytokines (e.g. IL-4, IL-5) may be 
involved (Hendrickson et al., 2002) (Table 9). In CD, treatment with the TNF-α 
binding monoclonal antibody, infliximab, has proven beneficial in active disease 
refractory to steroids or other conventional treatment (Targan et al., 1997; 
Monteleone and MacDonald, 2000). As yet, no direct anti-cytokine therapy has been 
adopted for the treatment of UC.  
 
 
Table 9. Effects of some relevant cytokines in IBD. 
 
Cytokine Produced by Function 
 
IL-1β 
 
Macrophages, neutrophils 
 
Activation of immune cells 
 
IL-2 
 
Activated T-cells, TH1 
 
T-cell proliferation, epithelial restitution 
 
IL-4 
 
TH2 cells, mast cells 
 
Lymphocyte function activation, macrophage 
function depression 
 
IL-5 
 
TH2 cells, mast cells, eosinophils 
 
Eosinophil differentiation, inhibition of 
apoptosis, etc.  
 
IL-6 
 
Macrophages, epithelial cells, 
endothelial cells TH2 cells, etc. 
 
Lymphocyte activation, inhibition of T-cell 
apoptosis 
 
IL-7 
 
Epithelial cells 
 
Regulation of lymphocyte proliferation, 
activation of monocytes and macrophages 
 
IL-8 
 
Macrophages, epithelial cells, 
fibroblasts 
 
Chemoattraction, activation of neutrophils 
 
IL-10 
 
T-cells, B-cells, activated monocytes 
 
Inhibition of cytokine production 
 
IL-12 
 
Activated macrophages, B-cells 
 
TH1 differentiation, IFN-γ production 
 
IL-18 
 
Macrophages, epithelial cells, etc. 
 
Promotion of TH1 differentiation, IFN-γ 
production 
 
IFN-γ 
 
TH1 cells, natural killer cells 
 
Activation of macrophages, inhibition of TH2 
cells 
 
TNF-α 
 
Macrophages 
 
Activation of immune and inflammatory cells 
IFN-γ, interferon-gamma; IL, interleukin; TH1, T-helper subtype 1 -cells; TNF-α, tumor necrosis factor alpha 
 
Despite the suggested differences in cytokine profiles between UC and CD, in active 
inflammation there is an increased production of inflammation promoting pleiotropic 
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cytokines, e.g. IL-1β, IL-6, INF-γ, and TNF-α, in both disease states suggestive of a 
non-IBD specific event, but rather an inflammation reflecting response (Reimund et 
al., 1996a; Reimund et al., 1996b; Fiocchi, 1998; Ishiguro, 1999). 
 
2.4.4 Current therapy 
The therapy of IBD first evolved as an empirical anti-inflammatory and antibiotic 
treatment with the anti-rheumatic, sulfasalazine (SASP). The anti-inflammatory 
moiety of SASP, 5-aminosalicylic acid is devoid of the adverse effects associated 
with SASP (skin rash, hepatitis, agranulocytosis, sperm abnormalities) and its 
antibiotic and carrier moiety, sulfapyridine. 5-ASA is currently used to treat mild to 
moderate IBD and also as the most common maintenance therapy. It exerts its 
effects locally within the inflamed mucosa (Hanauer and Dassopoulos, 2001).  
 
Oral, rectal and systemic steroids are used for treatment of exacerbations of IBD 
(Hanauer and Baert, 1995; Parkes and Jewell, 2001). Steroids have broad spectrum, 
nonspecific anti-inflammatory actions, and their continued administration is limited by 
dose- and duration-dependent side effects.  
 
Immunomodulatory therapies such as azathioprine, its metabolite 6-mercapto-purine, 
cyclosporin, tacrolimus, methotrexate, mycophenolate, and anti-cytokine –therapy 
with infliximab (anti-TNF-α) counteract the pathologic activation of T-cells and the 
production of cytokines and cytokine actions (Hanauer and Dassopoulos, 2001). 
Despite these various treatment strategies and their combination therapies, 
inflammation in IBD may persist or relapse. Even if remission is induced, sometimes 
the drugs’ adverse effects are so severe that only surgical removal of the inflamed 
bowel is left as an option. In UC, proctocolectomy is regarded as a curative treatment 
because of the disease’s limited nature to the colon and rectum (Hanauer and Baert, 
1995). After a successful operation and ileoanal-anastomosis, these patients can live 
a relatively normal life. However in CD several surgical approaches and bowel 
resections may be required to induce a quiescent state (Parkes and Jewell, 2001). 
Since inflammation in CD may occur in any part of the GI-tract, curative surgical 
treatment using bowel resections is virtually impossible.  
 
There is growing need for additional options in the treatment repertoire in IBD 
(Hanauer and Dassopoulos, 2001). Novel approaches include antagonism or 
inhibition of cytokine actions or transcription factor activity, suppression of adhesion 
molecule expression, reconstitution of nonpathogenic intestinal bacteria, promotion of 
epithelial repair, anti-oxidative therapies and also inhibition of inflammation specific 
enzymes e.g. COX-2 and iNOS (Blumberg and Strober, 2001). 
 
Even if the NOS-, COX-, and cytokine-pathways in inflammation are regarded as 
promising targets for therapy, the currently used drugs are not without effect on these 
parameters.  In in vitro studies aminosalicylates have been shown to downregulate 
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transcription and production of iNOS (Kennedy et al., 1999) and cytokines 
(Rachmilewitz et al., 1992), and to inhibit COX (Warner et al., 1999) and 5-LOX 
(Peskar et al., 1987) –enzymes. Aminosalicylates have also anti-oxidantive functions 
as scavengers of reactive oxygen species (Greenfield et al., 1993). The additional 
beneficial actions of aminosalicylates on inflammation and the fact that these drugs 
are quite well tolerated by patients may extend and bring new rationale to their use 
as primary medical care in IBD; in introducing and maintaining remission. 
 
Glucocorticoids are potent suppressors of inducible genes in inflammation (Barnes, 
1995). In active IBD, iNOS expression is not suppressed by glucocorticoid treatment 
(Leonard et al., 1998), even though profound effects on COX-2 expression are to be 
found (Barnes, 1995). Immunosuppressive drugs, aimed at suppressing T-cell 
functions, downregulate the production of T-cell -derived cytokines and thus reduce 
the iNOS and COX-2 transcription promoting stimuli. As pointed out previously, 
glucocorticoids and immunosuppressive drugs have numerous adverse effects such 
as: immunecompromisation of the patient, bone marrow suppression, and inceased 
susceptibility for cancer as well as the classic adverse effects of glucocorticoids 
(Barnes, 1995). Glucocorticoids are effective in the treatment of moderate to severe 
active disease, they are less efficacious as a maintenance therapy (Hanauer and 
Dassopoulos, 2001).  
 
Immunosuppressive therapy (cyclosporine, tacrolimus, methotrexate, azathioprine) 
potently downregulates T-cell functions, suppresses cytokine production and release 
(Sands, 2000). As these pro-inflammatory cytokines activate the transcription of 
iNOS and COX-2 genes, immunosuppressive therapy may also reduce NO and 
prostanoid production. These drugs have been shown to directly inhibit iNOS via 
inhibition on the level of protein synthesis or post-translationally (Dusting et al., 
1999). 
 
2.4.5 Novel therapies 
Currently cytokine-oriented therapy of IBD is limited to treatment of CD with infliximab 
or etanercept, antibodies that bind TNF-α and thus limit its activity (Bell and Kamm, 
2000). According to the present European guidelines on the use of anti-tumor 
necrosis factor agents the efficacy of infliximab in inducing remission is 33%, and 
improvement is found in 81% of patients with refractory CD (Schreiber et al., 2001). 
In most cases remission lasts for up to 8-12 weeks. If the first infusion of infliximab 
was ineffective, a second infusion of infliximab (usually after a 4 week interval) 
provides benefits in only a small portion of patients. The usefulness of anti-TNF-α 
therapy in UC is questionable since no clear beneficial effect has been seen 
(Schreiber et al., 2001). 
Therapy of IBD with IL-10 has also been evaluated in clinical trials (van Deventer et 
al., 1997; Fedorak et al., 2000; Schreiber et al., 2000). IL-10 is an anti-inflammatory 
cytokine, which suppresses the formation of inflammatory cytokines such as IL-1,   
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IL-6, and TNF-α (Narula et al., 1998). It has been shown to have therapeutic efficacy 
in clinical trials in CD (Fedorak et al., 2000; Sands, 2000). In studies done on UC-
patients, no clear improvement in disease activity was found in response to IL-10 
administration (Sands, 2000). 
 
Other therapies currently under study, mainly for the steroid dependent patients, 
include thalidomide, heparin, mycophenolate mofetil, anti-intercellular adhesion 
molecule-1, and anti-oxidant oriented therapies (Sands, 2000). Diet, or the use of 
probiotics or prebiotics to attain favorable/tolerable intestinal microbiota may also 
provide additional help for some patients (Campieri and Gionchetti, 1999; Shanahan, 
2001). 
 
2.5 Experimental models of inflammatory bowel diseases 
For studying the effects of experimental treatments in vivo, numerous experimental 
models of colitis have been developed (Table 10) (Elson et al., 1995; Sartor, 1997; 
Elson et al., 1998; Strober et al., 2002). All these models mimic some known features 
of human IBD, nevertheless the ideal experimental model as well as treatment have 
yet not been found due to the unknown etiology of IBD. These experimental models 
can be divided into chemically-induced, immune reconstitution associated, and 
spontaneously occurring in genetically susceptible strains or species. Due to their low 
costs and ease of establishment, the chemically induced models have been the most 
widely used for evaluation of novel drug treatments.  
 
2.5.1 2,4,6-Trinitrobenzenesulfonic acid (TNBS)–induced colitis 
The 2,4,6-trinitrobenzenesulfonic acid (TNBS, Figure 3) in ethanol -induced colitis is 
a widely used and reproducible model of both acute and chronic colitis (Neurath et 
al., 2000; Strober et al., 2002). It utilizes many aspects implicated in the 
pathogenesis of inflammatory bowel disease, such as initiation of inflammation by 
mucosal damage, activation of the immune system, increased nitrosative and 
oxidative stress. 
 
When TNBS-solution is administered to the colon, the ethanol component disrupts 
the intestinal epithelial barrier facilitating penetration of the hapten, TNBS (Morris et 
al., 1989). TNBS then couples trinitrophenyl groups to endogenous proteins, which in 
turn initiate immunologic activation (Cavani et al., 1995). TNBS modifies host cell 
protein lysine residues rendering these cells prone to recognition and lysis by 
cytotoxic T-cells and macrophages (Kunin and Gallily, 1983). The cellular enzymes 
may reduce TNBS to a nitro radical anion with concomitant formation of a superoxide 
radical thereby providing an additional mechanism for its inflammation inducing 
potential (Chamulitrat and Spitzer, 1997). Another contributing factor to TNBS toxicity 
is the formation of the sulfite radical, a mild oxidant and precursor of the highly 
cytotoxic sulfate and sulfiteperoxyl radicals (Chamulitrat, 1999).  
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Figure 3. Chemical structure of 2,4,6-trinitrobenzenesulfonic acid. 
 
In a colon carcinoma cell line, TNBS increased the production of COX-2 derived 
PGE2, PGI2 and LTB4 suggesting that TNBS acts directly and locally on epithelial 
cells (Stratton et al., 1996). The epithelial cell activation significantly contributes to 
the formation of eicosanoids by a mechanism unrelated to immune activation in 
TNBS-induced colitis. Colonocytes possess nitroreductase activity and enhance the 
production of TNBS-nitro radical anions, which catalyze the formation of superoxide 
radical anion from molecular oxygen (Grisham et al., 1991; Chamulitrat and Spitzer, 
1997). Superoxide and its metabolite hydrogen peroxide in turn activate NF-kappaB 
and induce iNOS (Adcock et al., 1994) and COX-2 (von Knethen et al., 1999) 
expression and activity.  
 
In TNBS-induced inflammation increased mucosal damage, ulcerations, and edema 
are limited to the distal colon, the place of the initial topical insult (Morris et al., 1989; 
Rachmilewitz et al., 1989). Colitis is associated with fasting and diarrhea (Morris et 
al., 1989). Dysfunctional changes in motility (alterations in contractility and neuronal 
function) are found in the inflamed and uninflamed colon and ileum (Jacobson et al., 
1997; Aube et al., 1999; Hosseini et al., 1999). In the acute stage of inflammation 
there is marked infiltration of granulocytes and increased production of cytokines IL-
1β, IL-6, and TNF-α (Sun et al., 2001). The chronic lesions in TNBS-induced colitis 
are dominated by lymphocytes and macrophages, and there is increased production 
of cytokines e.g. IFN-γ, IL-1, IL-6, IL-12 and TNF-α (Elson et al., 1996; Sun et al., 
2001). This pattern is suggestive of TH1 type activation. Increased production of 
various inflammatory mediators, e.g. PGE2, PGI2, TXB2, LTB4, and LTC4 has been 
reported in TNBS-colitis (Kim and Berstad, 1992). 
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Histologically the transmural lesions (Morris et al., 1989) are similar to the damage 
seen in CD. Similar to active human IBD, in TNBS-colitis there is increased 
expression of the inflammatory enzymes iNOS (Miampamba and Sharkey, 1999) and 
COX-2 (Nakase et al., 2001), increased production of peroxynitrite, and increased 
epithelial cell death (Yamada et al., 1992; Yue et al., 2001). Intestinal permeability is 
increased (Gardiner et al., 1995), and bacterial endotoxins find their way to the 
systemic circulation (Brand et al., 1994; Gardiner et al., 1995; Neilly et al., 1995). 
After resolution, colitis can be reactivated by intravenous TNBS (Appleyard and 
Wallace, 1995). Inflammation is ameliorated by introducing prehaptenated proteins 
orally prior to induction of colitis (Elson et al., 1996) and by treatment with a 
neutralizing antibody to IL-12 (Neurath et al., 1995). The precise pattern of the 
inflammatory response is dependent on the animal genotype, for example in BALB/c 
mice, the chronic stage is TH2 dominant and the lesions representative of UC (Dohi 
et al., 1999). When compared to Sprague-Dawley rats, for Wistar-strain rats the time-
span of the inflammatory response is usually shorter, being 6 weeks and 1 week, 
respectively (Morris et al., 1989; Moreels et al., 2001). 
 
2.5.2 Nitric oxide-related treatment of experimental colitis  
In TNBS-colitis the production of NO and the activity of iNOS are increased and 
associated with increased production of peroxynitrite and cell damage just like in the 
human disease (see 2.2). Since NO-metabolism serves as a common end-point 
effector in inflammation, its manipulation has been targeted in the treatment of colitis. 
The earlier unavailability of selective inhibitors of iNOS has ment that ambiguous 
results have been obtained. This has been overcome by administering non-selective 
inhibitors at different time points after the induction of inflammation. The rationale 
behind this is inhibition of constitutive enzymes by pretreatment or concomitant drug 
administration to colitis induction. Because the induction of iNOS requires de novo 
synthesis of protein, delayed administration of a non-selective inhibitor would 
simulate selective iNOS inhibition. By this rationale and the use of a non-selective 
NOS-inhibitor, L-NAME, it was shown, that delayed inhibition of NOS has a beneficial 
action on colitis (Kiss et al., 1997).  
 
Effects of some NOS-inhibitors in experimental models of colitis are shown in Table 
11. It has been speculated that also the route of drug administration plays a major 
role in determining a beneficial or detrimental effect. There are data suggesting that 
systemic administration of iNOS inhibitors or topical administration of a nonselective 
inhibitor at time of most iNOS activity show beneficial effects (Table 11). These drug 
effects have been studied in only a limited number of models, and their effects need 
to be evaluated in human tissues. In conclusion, nitric oxide and its metabolites have 
been shown to be mediators of inflammation by use of these models of colitis. 
Manipulation of the L-arginine-nitric oxide –pathway, and specifically the suppression 
of iNOS, are likely to be of therapeutic value in the treatment of IBD. 
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Changes in NO-metabolism and/or availability are achieved also by indirect means. 
For example, treatment of colitis with a superoxide dismutase mimicking drug 
increases the availability and putative anti-inflammatory actions of increased NO 
while inhibiting NO reactivity by decreasing O2- and the production of toxic ONOO- 
(Cuzzocrea et al., 2001a). Similarly, treatment with anti-oxidants has been reported 
to suppress experimental colitis (Cuzzocrea et al., 2000). It has also been shown that 
inhibition of NF-kappaB activation by oligonucleotides (Neurath et al., 1996), or 
inhibition of the degradation of the endogenous NF-kappaB inhibitor, I-kappaB, 
ameliorates colitis (Conner et al., 1997; Cuzzocrea et al., 2001c). NF-kappaB is 
activated in experimental colitis (Neurath et al., 1996; Marrero et al., 2000) as well as 
in human IBD (Schreiber et al., 1998), where it is associated with active inflammation 
(Ardite et al., 1998; Egan and Sandborn, 1998). Less severe colitis has been 
reported in poly(adenosinediphosphate-ribose)synthetase (PARS)-deficient mice 
(Zingarelli et al., 1999a) as well as in iNOS deficient mice (Zingarelli et al., 1999b). 
PARS is activated in response to cell and tissue injury by e.g. ONOO-. The activation 
of PARS, however, depletes the cell of its energy stores thus contributing to 
increased apoptosis and tissue destruction (Szabo et al., 1996). 
 
In experimental colitis models inhibition of iNOS-derived NO production and ONOO- 
formation results in the development of less severe forms of disease. Results with 
iNOS inhibitors such as aminoguanidine cannot be readily interpreted, since these 
inhibitors possess iNOS-unrelated effects (see 2.2.1). However, the recent literature 
and experimental data point to the fact that inhibition of increased NO synthesis may 
provide benefit in IBD. 
 
2.5.3 Eicosanoid-related treatment of experimental colitis 
The effects on experimental models of colitis of COX-inhibitors or E-series 
prostaglandin supplementation are shown in Table 12. Drugs with selectivity for the 
inducible isoform, COX-2 have been shown to have beneficial effects, while 
nonselective inhibitors like indomethacin or naproxen have exacerbated the 
inflammatory lesions in both acute and chronic models. However, supplementation 
with analogs of E-series prostaglandins such as enprostil, misoprostol or alprostadil 
has had consistently beneficial effects in different models of experimental colitis. 
COX-2 has been shown to have anti-inflammatory effects and to play a crucial role in 
resolution of inflammation (Morteau et al., 2000; Halter et al., 2001).  
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 a
re
a↓
,
 
co
lo
n
 w
ei
gh
t↓
,
 
M
PO
-
ac
tiv
ity
↓
,
 
NO
S-
ac
tiv
ity
↓
,
 
TN
F-
α
↓
,
 
IL
-
1β
↓
,
 
hi
st
o
lo
gi
ca
l in
fla
m
m
at
io
n
↓
 
(K
ar
m
el
i  e
t a
l.,
 
20
00
) 
 
s.
c.
 
4 
da
ys
 
pr
io
r 
to
 
in
du
ct
io
n
 
25
 m
g/
kg
 
TN
BS
,
 
ra
ts
 
24
 h
ou
rs
 
Be
ne
fic
ia
l 
Le
si
o
n
 a
re
a
↓
,
 
M
PO
-
ac
tiv
ity
↓
,
 
in
fla
m
m
at
or
y 
ed
em
a↓
,
 
bo
dy
 w
ei
gh
t 
lo
ss
↓
 
(G
uo
 
et
 
al
.
,
 
20
01
) 
 
p.
o.
 
1 
da
y 
pr
io
r 
to
 
in
du
ct
io
n
 
5 
m
g/
kg
 
DS
S,
 
ra
ts
 
2 
da
ys
 
Be
n
ef
ici
al
 
DN
A 
da
m
ag
e ↓
,
 
ap
o
pt
os
is↑
 
No
 n
eu
tro
ph
il i
n
filt
ra
tio
n 
in
 
th
is 
m
od
el
! 
(Ta
rdi
eu
 
et
 
al
.
,
 
20
00
) 
NS
-
39
8 
p.
o.
 
1 
ho
ur
 p
rio
r 
to
 
in
du
ct
io
n
 
1-
10
0 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
2 
da
ys
 
No
 e
ffe
ct
 
No
 C
O
X-
2 
ex
pr
es
si
on
/P
G
E 2
 
fo
rm
at
io
n
 
in
 
in
fla
m
ed
 
co
lo
n
 
in
 
th
is 
m
o
de
l! 
(Le
sc
h 
et
 
al
.
,
 
19
99
) 
SC
-
58
12
5 
p.
o.
 
1 
ho
ur
 p
rio
r 
to
 
in
du
ct
io
n
 
1-
10
0 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
2 
da
ys
 
No
 e
ffe
ct
 
No
 C
O
X-
2 
ex
pr
es
si
on
/P
G
E 2
 
fo
rm
at
io
n
 
in
 
in
fla
m
ed
 
co
lo
n
 
in
 
th
is 
m
o
de
l! 
(Le
sc
h 
et
 
al
.
,
 
19
99
) 
PD
-
13
83
87
 
p.
o.
 
 
1 
ho
ur
 p
rio
r 
to
 
in
du
ct
io
n
 
1-
10
0 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
2 
da
ys
 
No
 e
ffe
ct
 
No
 C
O
X-
2 
ex
pr
es
si
on
/P
G
E 2
 
fo
rm
at
io
n
 
in
 
in
fla
m
ed
 
co
lo
n
 
in
 
th
is 
m
o
de
l! 
(Le
sc
h 
et
 
al
.
,
 
19
99
) 
Ac
et
yls
al
icy
lic
 
ac
id
 
p.
o.
 
2 
we
ek
s 
af
te
r 
in
du
ct
io
n
 
10
0 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
No
 e
ffe
ct
 
M
ac
ro
sc
op
ic 
da
m
ag
e 
-
 
(B
ou
gh
to
n-
Sm
ith
 
et
 
al
.
,
 
19
88
) 
In
do
m
et
ha
ci
n
 
i.m
.
 
5 
da
ys
 
pr
e-
tre
at
m
en
t o
nl
y 
 
2.
5 
m
g/
kg
 
Ac
et
ic 
ac
id
,
 
ra
ts
 
2 
da
ys
 
De
tri
m
en
ta
l 
M
ac
ro
sc
op
ic 
da
m
ag
e↑
,
 
M
PO
-
ac
tiv
ity
 
-
,
 
flu
id
 a
bs
or
bt
io
n
↓
 
 
(E
m
pe
y 
et
 
al
.
,
 
19
92
) 
 
s.
c.
 
At
 ti
m
e 
o
f 
in
du
ct
io
n
 
2 
m
g/
kg
 
Pe
pt
id
og
lyc
an
 
po
lys
ac
ch
ar
id
e,
 
ra
ts
 
7 
da
ys
 
De
tri
m
en
ta
l 
IL
-
1α
↑
,
 
M
PO
-
ac
tiv
ity
↑
 
(K
an
di
l e
t a
l.,
 
19
99
) 
 
s.
c.
 
4 
da
ys
 
pr
io
r 
to
 
in
du
ct
io
n
 
2.
5 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
24
 h
ou
rs
 
Be
ne
fic
ia
l  
M
PO
-a
ct
iv
ity
↓
,
 
co
lo
ni
c 
ed
em
a↓
,
 
bo
dy
 
w
ei
gh
t l
o
ss
↓
,
 
le
si
on
 a
re
a 
- 
(G
uo
 
et
 
al
.
,
 
20
01
) 
 
i.p
. 
24
 h
ou
rs
 
af
te
r 
in
du
ct
io
n
 
5 
m
g/
kg
 
Ac
et
ic 
ac
id
,
 
ra
ts
 
5 
da
ys
 
De
tri
m
en
ta
l 
Le
si
on
 a
re
a
↑
 
(Le
Du
c e
t a
l.,
 
19
93
) 
 
s.
c.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
0.
1-
1 
m
g/
kg
 
x2
 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
De
tri
m
en
ta
l 
M
PO
↑
,
 
m
o
rta
lit
y↑
,
 
co
lo
n 
m
ac
ro
sc
op
ic
 
da
m
ag
e ↑
 
(W
al
la
ce
 
et
 
al
.
,
 
19
92
) 
 
p.
o
. 
At
 
tim
e 
o
f 
in
du
ct
io
n
 
10
 m
g/
kg
 
TN
BS
,
 
ra
ts
 
3 
ho
ur
s 
D
et
rim
en
ta
l 
M
PO
↑
,
 
PG
D 2
↓
 
(A
jue
bo
r e
t a
l.,
 
20
00
) 
 
41 
  
42
 
Ta
bl
e 
12
. C
on
tin
ue
d.
 
Tr
e
at
m
e
n
t o
f e
xp
er
im
en
ta
l c
ol
iti
s 
wi
th
 c
yc
lo
ox
yg
e
n
a
se
 in
hi
bi
to
rs
 
o
r 
pr
o
st
ag
la
nd
in
 a
n
a
lo
gs
. 
 
Dr
u
g 
Ro
u
te
 o
f 
ad
m
in
is
-
tr
at
io
n 
Be
gi
nn
in
g 
o
f 
tr
ea
tm
en
t 
Da
ily
 
do
se
 
M
od
el
 
o
f c
o
lit
is
 
Du
ra
tio
n
 o
f 
ex
pe
rim
en
t 
Ef
fe
ct
 
B
en
ef
ic
ia
l/ 
D
et
rim
en
ta
l 
D
et
ai
le
d 
ef
fe
ct
s 
R
ef
er
en
ce
 
In
do
m
et
ha
ci
n
 
i.m
.
 
Fr
om
 
da
y 
7 
to
 
da
y 
21
 fr
om
 
in
du
ct
io
n
 
1 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
21
 d
ay
s 
No
 e
ffe
ct
 
M
ac
ro
sc
op
ic 
an
d 
hi
st
ol
og
ic 
da
m
ag
e 
-
 
(V
ila
se
ca
 
et
 
al
.
,
 
19
90
)
 
p.
o.
 
2 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
10
 m
g/
kg
 x
2 
Fo
rm
al
in
-
im
m
u
n
ec
om
pl
ex
,
 
ra
bb
its
 
2 
da
ys
 
No
 e
ffe
ct
 
In
fla
m
m
at
o
ry
 c
el
l in
de
x 
-
,
 
ex
u
da
te
 -
, 
ed
em
a 
-
,
 
n
ec
ro
sis
 
-
 
 
(S
ch
um
er
t e
t a
l.,
 
19
88
) 
 
i.m
.
 
1 
ho
ur
 p
rio
r 
to
 
in
du
ct
io
n
 
2 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
3 
da
ys
 
No
 e
ffe
ct
 
M
ac
ro
sc
op
ic 
da
m
ag
e 
-
 
(H
os
hi
n
o
 
et
 
al
.
,
 
19
92
) 
 
i.m
.
 
Fr
om
 
da
y 
4 
af
te
r 
in
du
ct
io
n 
2 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
14
 d
ay
s 
No
 e
ffe
ct
 
M
ac
ro
sc
op
ic 
da
m
ag
e 
-
 
(H
os
hi
n
o
 
et
 
al
.
,
 
19
92
) 
 
p.
o.
 
24
 h
ou
rs
 
af
te
r 
in
du
ct
io
n
 
2.
25
 m
g/
kg
 
Ac
et
ic 
ac
id
,
 
ra
ts
 
6 
da
ys
 
De
tri
m
en
ta
l 
M
PO
-a
ct
iv
ity
↑
 
(Fi
tz
pa
tri
ck
 
et
 
al
.
,
 
19
90
) 
 
p.
o.
 
2 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
2.
25
 m
g/
kg
 
Ac
et
ic 
ac
id
,
 
ra
ts
 
24
 h
ou
rs
 
No
 e
ffe
ct
 
M
ac
ro
sc
op
ic 
da
m
ag
e 
-
 
(Fi
tz
pa
tri
ck
 
et
 
al
.
,
 
19
90
) 
 
p.
o.
 
2 
we
ek
s 
af
te
r 
in
du
ct
io
n 
0.
5 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
No
 e
ffe
ct
 
M
ac
ro
sc
op
ic 
da
m
ag
e 
-
 
(B
ou
gh
to
n-
Sm
ith
 
et
 
al
.
,
 
19
88
) 
 
p.
o
. 
1 
ho
ur
 p
rio
t t
o
 
in
du
ct
io
n
 
10
 m
g/
kg
 
Io
do
ac
et
am
id
e,
 
ra
ts
 
3 
da
ys
 
De
tri
m
en
ta
l 
Le
si
on
 a
re
a
↑
,
 
M
PO
 
ac
tiv
ity
↑
,
 
ed
em
a↓
 
(S
at
oh
 
et
 
al
.
,
 
19
97
) 
In
do
m
et
ha
ci
n 
(I) 
+
 
m
is
op
ro
st
ol
e 
(M
) 
p.
o
.+
 i.
r.
 
5 
da
ys
 
(I) 
+
 3
0 
m
in
 (M
) p
rio
r 
to
 
in
du
ct
io
n 
on
ly 
2.
5 
m
g/
kg
 
+
 
10
0 
µg
/k
g 
Ac
et
ic 
ac
id
,
 
ra
ts
 
2 
da
ys
 
Be
ne
fic
ia
l 
M
ac
ro
sc
op
ic 
u
lce
ra
tio
ns
↓
 
 
(E
m
pe
y 
et
 
al
.
,
 
19
92
) 
 
s.
c.
 
At
 ti
m
e 
o
f 
in
du
ct
io
n
 
2 
m
g/
kg
 +
 
90
 µ
g/
kg
 
Pe
pt
id
og
lyc
an
 
po
lys
ac
ch
ar
id
e,
 
ra
ts
 
7 
da
ys
 
Be
ne
fic
ia
l 
In
do
m
et
ha
ci
n
 
in
du
ce
d 
IL
-
1α
↓
 
an
d 
M
PO
-
ac
tiv
ity
↓
 
(K
an
di
l e
t a
l.,
 
19
99
) 
Na
pr
ox
en
l 
s.
c.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
5 
m
g/
kg
 x
2 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
De
tri
m
en
ta
l 
M
PO
-a
ct
iv
ity
↑
,
 
m
o
rta
lit
y↑
,
 
co
lo
n 
m
ac
ro
sc
op
ic 
da
m
ag
e ↑
 
(W
al
la
ce
 
et
 
al
.
,
 
19
92
) 
 
p.
o.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
5 
m
g/
kg
 x
2 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
De
tri
m
en
ta
l 
M
o
rta
lit
y↑
 
(R
eu
ter
 
et
 
al
.
,
 
19
96
) 
Di
cl
of
en
ac
 
p.
o.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
10
 m
g/
kg
 x
2 
TN
BS
,
 
ra
ts
 
3 
da
ys
 
De
tri
m
en
ta
l  
M
ac
ro
sc
op
ic 
an
d 
hi
st
ol
og
ic 
da
m
ag
e
↑
,
 
M
PO
 
-
 
(R
eu
ter
 
et
 
al
.
,
 
19
96
) 
 
p.
o.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
10
 m
g/
kg
 x
2 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
De
tri
m
en
ta
l 
M
o
rta
lit
y↑
 
(R
eu
ter
 
et
 
al
.
,
 
19
96
) 
Na
bu
m
et
on
e 
p.
o.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
75
 m
g/
kg
 x
2 
TN
BS
,
 
ra
ts
 
3 
da
ys
 
De
tri
m
en
ta
l 
M
ac
ro
sc
op
ic 
an
d 
hi
st
ol
og
ic 
da
m
ag
e
↑
,
 
M
PO
 
-
 
(R
eu
ter
 
et
 
al
.
,
 
19
96
) 
 
p.
o.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
25
 m
g/
kg
 x
2 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
De
tri
m
en
ta
l 
M
o
rta
lit
y↑
 
(R
eu
ter
 
et
 
al
.
,
 
19
96
) 
L7
45
,3
37
 
p.
.
o
.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
5 
m
g/
kg
 x
2 
TN
BS
,
 
ra
ts
 
3 
da
ys
 
De
tri
m
en
ta
l 
M
ac
ro
sc
op
ic 
an
d 
hi
st
ol
og
ic 
da
m
ag
e
↑
,
 
M
PO
 
-
 
(R
eu
ter
 
et
 
al
.
,
 
19
96
) 
 
p.
o.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
5 
m
g/
kg
 x
2 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
De
tri
m
en
ta
l 
M
o
rta
lit
y↑
 
(R
eu
ter
 
et
 
al
.
,
 
19
96
) 
Et
od
ol
ac
 
p.
o.
 
3 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
10
 m
g/
kg
 x
2 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
De
tri
m
en
ta
l 
M
o
rta
lit
y↑
 
(R
eu
ter
 
et
 
al
.
,
 
19
96
) 
 
42 
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Ta
bl
e 
12
. C
on
tin
ue
d.
 
Tr
e
at
m
e
n
t o
f e
xp
er
im
en
ta
l c
ol
iti
s 
wi
th
 c
yc
lo
ox
yg
e
n
a
se
 in
hi
bi
to
rs
 o
r 
pr
o
st
ag
la
nd
in
 a
n
a
lo
gs
. 
 
Dr
u
g 
Ro
u
te
 o
f 
ad
m
in
is
-
tr
at
io
n 
Be
gi
nn
in
g 
o
f 
tr
ea
tm
en
t 
Da
ily
 
do
se
 
M
od
el
 
o
f c
o
lit
is
 
Du
ra
tio
n
 o
f 
ex
pe
rim
en
t 
Ef
fe
ct
 
B
en
ef
ic
ia
l/ 
D
et
rim
en
ta
l 
D
et
ai
le
d 
ef
fe
ct
s 
R
ef
er
en
ce
 
En
pr
os
til 
(P
G
E 2
) 
i.r
. 
 
1 
we
ek
 
af
te
r 
DS
S 
~
50
-2
50
 µ
g/
kg
 
(10
 µg
 
or
 5
0 
µg
) 
DS
S,
 
ra
ts
 
1 
we
ek
 
Be
n
ef
ici
al
 
M
ac
ro
sc
op
ic 
an
d 
hi
st
ol
og
ic 
le
si
o
n
s ↓
,
 
M
PO
↓
,
 
IL
-
1β
↓
 
(S
as
ak
i  e
t a
l.,
 
20
00
) 
Al
pr
os
ta
di
l 
(P
G
E 1
) 
i.p
. 
12
 h
ou
rs
 
af
te
r 
in
du
ct
io
n
 
~
10
 µ
g/
kg
 
(2 
µg
) 
Ac
et
ic 
ac
id
,
 
ra
ts
 
3-
10
 d
ay
s 
Be
n
ef
ici
al
 
at
 
3 
da
ys
 
M
ac
ro
sc
op
ic 
an
d 
hi
st
ol
og
ic 
da
m
ag
e↓
 
(Te
rzi
og
lu
 
et
 
al
.
,
 
19
97
) 
16
,1
6-
di
m
et
hy
l 
PG
E 2
 
i.r
. 
20
 m
in
u
te
s 
pr
io
r 
to
 
in
du
ct
io
n 
20
00
 µ
g/
kg
 
Bu
ty
ric
 a
ci
d,
 
m
ice
5 
ho
ur
s 
Be
ne
fic
ia
l 
Ed
em
a
↓
,
 
M
PO
-
ac
tiv
ity
↓
,
 
m
ac
ro
sc
op
ic 
in
fla
m
m
at
io
n ↓
 
(M
cC
af
fe
rty
 a
nd
 Z
ei
tli
n,
 
19
92
)
 
s.
c.
 
2 
ho
ur
s 
pr
io
r 
to
 
in
du
ct
io
n
 
10
0 
µg
/k
g 
Fo
rm
al
in
-
im
m
u
n
ec
om
pl
ex
,
 
ra
bb
its
 
2 
da
ys
 
Be
n
ef
ici
al
 
In
fla
m
m
at
or
y 
ce
ll 
in
de
x↓
,
 
n
ec
ro
sis
↓
,
 
ex
u
da
te
 
↓
,
 
ed
em
a↓
 
(S
ch
um
er
t e
t a
l.,
 
19
88
) 
 
i.r
. 
45
 m
in
 p
rio
r 
to
 
or
 
24
 h
 a
fte
r 
in
du
ct
io
n
 
20
 m
g/
kg
 
TN
BS
,
 
ra
ts
 
3 
da
ys
 
Be
ne
fic
ia
l 
M
ac
ro
sc
o
pi
c 
in
fla
m
m
at
io
n ↓
,
 
M
PO
-
ac
tiv
ity
↓
 
(A
llg
ay
er
 
et
 
al
.
,
 
19
89
) 
 
i.r
. 
20
 m
in
 p
rio
r 
to
 
in
du
ct
io
n
 
0.
2-
20
 µ
g/
kg
 
Et
ha
no
l, 
ra
ts
 
10
 m
in
u
te
s 
Be
ne
fic
ia
l 
M
ac
ro
sc
op
ic 
an
d 
hi
st
ol
og
ica
l 
in
fla
m
m
at
io
n
↓
,
 
ce
ll d
isr
u
pt
io
n
↓
 
(W
al
la
ce
 
et
 
al
.
,
 
19
85
) 
M
is
op
ro
st
o
l 
s.
c.
 
At
 
tim
e 
of
 
in
du
ct
io
n 
90
 µ
g/
kg
 
Pe
pt
id
og
lyc
an
 
po
lys
ac
ch
ar
id
e,
 
ra
ts
 
7 
da
ys
 
Be
n
ef
ici
al
 
IL
-
1 α
↓
,
 
M
PO
-
ac
tiv
ity
↓
 
(K
an
di
l e
t a
l.,
 
19
99
) 
 
i.r
. 
30
 m
in
u
te
s 
pr
io
r 
to
 
in
du
ct
io
n
 
10
0 
µg
/k
g 
Ac
et
ic 
ac
id
,
 
ra
ts
 
2 
da
ys
 
Be
ne
fic
ia
l 
Co
lo
ni
c 
u
lce
ra
tio
ns
↓
,
 
hi
st
o
lo
gi
ca
l d
am
ag
e↓
,
 
re
st
or
es
 
m
uc
os
al
 
flu
id
 a
bs
o
rp
tio
n 
(Fe
do
rak
 
et
 
al
.
,
 
19
90
) 
 
i.r
. 
30
 m
in
u
te
s 
pr
io
r 
to
 
in
du
ct
io
n 
10
0 
µg
/k
g 
Ac
et
ic 
ac
id
,
 
ra
ts
 
2 
da
ys
 
Be
ne
fic
ia
l 
M
ac
ro
sc
op
ic 
in
jur
y↓
,
 
M
PO
-
ac
tiv
ity
↓
 
(E
m
pe
y 
et
 
al
.
,
 
19
92
) 
CO
X-
2 
cD
NA
 
ph
os
ph
ot
io
at
ed
 
o
lig
on
uc
le
ot
id
es
 
i.p
. 
1 
ho
ur
 
pr
et
re
at
m
en
t 
3 
m
g/
kg
 
TN
BS
,
 
ra
ts
 
7 
da
ys
 
Be
n
ef
ici
al
 
M
PO
 a
ct
iv
ity
↓
,
 
CO
X-
2 
ex
pr
es
si
o
n
↓
,
 
PG
E 2
 
↓
 
(K
ha
n 
et
 
al
.
,
 
20
01
) 
CO
X-
1 
-/-
 
 
 
 
DS
S,
 
m
ic
e 
5 
da
ys
 
Ex
ac
er
ba
tio
n 
 
(M
or
te
au
 
et
 
al
.
,
 
20
00
) 
CO
X-
2 
-/-
 
 
 
 
DS
S,
 
m
ic
e 
5 
da
ys
 
Ex
ac
er
ba
tio
n 
 
(M
or
te
au
 
et
 
al
.
,
 
20
00
) 
↑
/↓
,
 
in
cr
e
a
se
/d
ec
re
a
se
; -
,
 
n
o
 e
ffe
ct
; C
O
X,
 
cy
cl
oo
xy
ge
na
se
; D
N
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In colitis, the increased production of PGE2 and PGD2 is related to COX-2 induction 
and to anti-inflammatory effects (Ajuebor et al., 2000). Prostaglandin D2 and its 
metabolites PGJ2, 12-delta-PGJ2 and 15-deoxy-delta12,14-PGJ2 are produced in 
high amounts by mast cells, and also by enterocytes in inflammation (Longo et al., 
1998). They have been suggested to have both anti- and pro-inflammatory effects. In 
TNBS-induced colitis administration of PGD2 and its receptor agonist inhibited, while 
its metabolite increased infitration of neutrophil granulocytes (Ajuebor et al., 2000). 
The production of PGD2 in this TNBS-model of colitis was inhibited by celecoxib, a 
COX-2 selective NSAID (Ajuebor et al., 2000). In concert with that study showing 
aggravation of inflammation by PGD2 metabolites, 15-deoxy-delta12,14-PGJ2 has 
been shown to induce production of IL-8, a potent pro-inflammatory cytokine in 
human T-cells (Harris et al., 2002). However, PGJ2 has also been shown to have 
anti-inflammatory properties and to act as an endogenous agonist for peroxisome 
proliferator activated receptors (PPAR), mainly for PPAR-γ (Clark et al., 2000). In 
experimental colitis as well as in human disease beneficial anti-inflammatory effects 
with PPAR-γ agonists have been reported (Su et al., 1999; Lewis et al., 2001). It is 
interesting that some older NSAIDs, e.g. naproxen and indomethacin, can function as 
activators of PPAR-γ and may thereby extend their therapeutic benefits (Jaradat et 
al., 2001). 
 
During inflammation the production of PGI2 is co-induced with PGE2 (Ligumsky et al., 
1981; Brock et al., 1999). In PGI2-receptor deficient mice carrageenan-induced 
inflammatory edema was suppressed in a manner similar to indomethacin-treated 
wild-type mice suggesting that PGI2 signalling increases inflammatory swelling (Ueno 
et al., 2000). PGI2 receptors are also involved in pain perception (Murata et al., 
1997). Increased production of PGI2 has been associated with UC and CD, and 
shown to be inhibited by treatment with steroids and sulfasalazine (Ligumsky et al., 
1981). 
 
During inflammation, AA is also metabolized by the 5-lipoxygenase (5-LOX) pathway 
leading to the synthesis of leukotrienes (see 2.3.2). LTB4 is a very potent inducer of 
chemotaxis and an activator of neutrophil granulocytes (Yokomizo et al., 2001). The 
therapeutic potential of inhibition of 5-LOX and leukotriene synthesis was challenged 
in a multicenter study with 183 patients suffering from UC (Roberts et al., 1997). 
Despite a marked suppression of colonic LTB4 no beneficial effect was seen. A 
similar lack of effect has also been seen in TNBS-induced experimental colitis in the 
rat (Holma et al., 2001). 
 
Plasma concentrations and mucosal production of PGE2, and the inflammation in 
colitis are in direct correlation with each other (Wiercinska-Drapalo et al., 1999a). 
Measurement of plasma PGE2 has in fact been suggested to have a role as a 
surrogate marker of active disease (Wiercinska-Drapalo et al., 1999b). PGE2 has 
been shown to activate the T-helper 2 subtype and to suppress the T-helper 1 
subtype T-cells (Snijdewint et al., 1993; Katamura et al., 1995). In UC, there is a 
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predominance of a T-helper 2 subtype activation and an increase in type 2 cytokines, 
so by this rationale the inhibition of PGE2 production by e.g. NSAIDs could alleviate 
disease. On the other hand, PGE2 may inhibit the production of the pro-inflammatory 
cytokine, TNF-α (Kunkel et al., 1988). An increase in PGE2 would thus lead to 
beneficial anti-inflammatory effects through this mechanism. Treatment of 
experimental colitis with PGE-analogues, such as misoprostole, has shown promising 
results (Table 12). It has also been shown that inhibition of increased mucosal 
thromboxane synthesis or antagonism of the thromboxane effects in TNBS-induced 
rat colitis increases PGE2 concentrations and thereby exerts anti-inflammatory effects 
(Vilaseca et al., 1990; Taniguchi et al., 1997).  
 
Coupled to the release of AA from a membrane phospholipid backbone and PLA2 
activity is the formation of platelet activating factor (PAF). The synthesis of PAF from 
the remaining phospholipid (phosphatidylcholine) precursor after AA discharge is 
catalysed by a specific acetyltransferase. In addition to activation of thrombocyte 
aggregation, PAF functions as a potent chemotactic agent, it increases the 
accumulation and activation of neutrophil granulocytes, and modulates cytokine 
synthesis during inflammation (Prescott et al., 2000). The concentrations of PAF in 
inflamed mucosa of IBD patients (Wardle et al., 1996) and in experimental colitis are 
increased (Longo et al., 1994). One novel and attractive approach to treating IBD is 
through PAF antagonism. Beneficial effects in experimental colitis models utilizing 
this anti-inflammatory principle have been attained (Will et al., 1991; Meenan et al., 
1996). A combination releasing 5-ASA and a PAF antagonist in the colon was found 
to have beneficial effects in TNBS-colitis (Galvez et al., 2000). 
 
Other metabolites of AA have also been implicated in IBD. For example, 15-hydroxy-
eicosatetraenoic acid (15-HETE) was identified as the main eicosanoid formed by the 
colon mucosa (Zijlstra et al., 1992). Its synthesis correlated positively with the 
severity of colon inflammation suggesting a role for 15-lipoxygenase activity in IBD. 
Moreover, the expression of 12-LOX was induced in both UC and CD colitic mucosa 
and was undetectable in normal colon mucosa (Shannon et al., 1993). The role of 
12-HETE has been studied in cancer, where it is associated with an increased 
metastatic potential of cancer cells (Silletti et al., 1994; Yamamoto et al., 1997). 
 
Continuing inflammation in IBD predisposes to premalignant or malignant changes in 
the colon. NSAIDs reduce the incidence of colon cancer, and COX-2 is implicated in 
colon carcinogenesis (Prescott and Fitzpatrick, 2000). Treatment with a NO-releasing 
NSAIDs (nitrosulindac) potentiated the anti-proliferative effect of the parent 
compound (sulindac) on colon cancer cells (Lavagna et al., 2001).  
 
Colon epithelial cells undergo apoptosis in response to bacterial invasion (Kim et al., 
1998). In the TNBS-model of experimental colitis increased epithelial cell apoptosis is 
associated with peroxynitrite-induced cell damage and increased expression and 
activity of iNOS (Yue et al., 2001). Treatment with a NO-releasing mesalamine has 
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been shown to protect epithelial cells from cytokine-induced apoptosis (Fiorucci et al., 
2001) and to provide an enhanced anti-inflammatory effect in the TNBS-model of 
colitis in rats (Wallace et al., 1999). These anti-apoptotic effects of NO on normal 
epithelial cells are mediated by S-nitrosation and inactivation of caspase. This effect 
of NO may pose a threat of increased risk for carcinogenesis when considering 
treatment with NO-donors. Inhibition of apoptosis may allow survival of cells with 
genetic alterations i.e. putative cancer cells (Jaiswal et al., 2001). In contrast to these 
findings, the NO-releasing NSAIDs, as pointed out previously, have been shown to 
inhibit tumor cell proliferation and to decrease preneoplastic changes in a rat model 
of colon cancer (Bak et al., 1998) by a yet unidentified mechanism. Further studies 
will undoubtedly shed light on the role of NO-NSAIDs in inflammation and 
carcinogenesis. 
 
There is an increasing trend to produce chimeras where a novel acting compound is 
combined to a conventionally used drug in order to achieve additive or even 
synergistic effects. Good examples of this are the above-mentioned NO-releasing 
NSAID and 5-ASA – PAF antagonist combinations. There is an increasing body of 
evidence stating that inhibition of the rate-limiting enzyme in the formation of 
prostanoids may not be the most efficient anti-inflammatory strategy in the gut. 
Perhaps downstream enzyme inhibition from COX, selective prostanoid/ eicosanoid 
receptor antagonism or agonism, or a combination of multiple inhibitory/ activating 
molecules will provide the desired beneficial effects in the future; adverse effects 
aside. Moreover, the multifactorial pathogenesis of IBD that has eluded scientist and 
clinicians does not provide a solid basis for drug design. The disheartening clinical 
trials so far on manipulation of eicosanoid actions may still hold back the acceptance 
of drugs aimed at a prostanoid-eicosanoid-system for colitis patients. 
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3 AIMS OF THE STUDY 
 
The aim of this thesis was to investigate the roles of the inflammation associated 
inducible enzymes, iNOS and COX-2 in colitis. Their contribution was assessed by 
using NOS- and COX- enzyme inhibitors with different selectivities for the constitutive 
and inducible isoforms in an experimentally-induced model of colitis in the rat. The 
role of iNOS was further investigated in mucosal samples from patients with 
ulcerative colitis. 
 
The detailed aims were as following: 
 
1. To characterize a suitable, affordable, and reproducible experimental model for 
studying the role of NOS and COX –pathways in colitis and to find appropriate 
parameters of inflammation that could be used to quantitate the effects of drug 
treatments (Study I). 
 
2. To investigate the contributions of the COX-enzymes in gut inflammation by 
using inhibitors with different selectivities towards the two COX-isoforms in the 
TNBS-induced experimental model of colitis (Study II). 
 
3. To compare the effects of selective iNOS-inhibition and non-selective NOS-
inhibition in the TNBS-model of colitis in order to clarify the role of iNOS in this 
model (Study III). 
 
4. To extend the findings of Study III and to investigate further the anti-inflammatory 
effects of selective iNOS inhibition in human tissue and disease (Study IV). 
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4 MATERIALS AND METHODS 
 
The exact methods are to be found in the original Studies I-IV. 
 
4.1 Experimental setups  
4.1.1 Acute TNBS-colitis in the rat 
2,4,6-Trinitrobenzenesulfonic acid (TNBS) was diluted with 50% ethanol to obtain a 
final solution containing 60 mg/ml or 120 mg/ml TNBS. The male Wistar rats were 
anesthetized with halothane, and the TNBS-solution (1 ml/kg body weight) was 
administered rectally via a polypropene catheter in the distal colon seven centimeters 
proximally from the anus. The catheter was carefully withdrawn and the rat was left in 
a supine position to recover from anesthesia.  The rats were admitted normally to 
laboratory food and water before and after induction of colitis.  
 
The rats were decapitated, blood was collected and the distal colon was removed, 
weighed, and photographed. Blood was collected into heparinised tubes, and was 
immediately centrifuged, and plasma was collected. Three samples were cut from the 
distal part of the colon, and mucosa was scraped off from the remaining tissue for 
myeloperoxidase measurement. In Study I, samples of spleen were also taken. All 
samples were stored in a deep freezer (at –70 oC) before measurements. 
 
4.1.2 Incubation of human colon samples 
Colon mucosal samples were collected from patients with UC undergoing elective 
colectomy at the Helsinki University Central Hospital. Samples of mucosa with or 
without macroscopic inflammation were excised from the removed colon, washed in 
ice-cold physiological saline solution and dissected with a 4 mm diameter cuvette into 
samples for incubation. These samples were then washed in phosphate buffered 
saline (PBS) and incubated for 5 hours with or without the drugs under study. 
 
4.2 Measurements and methods 
4.2.1 Colon damaged area 
For quantitation of colon inflammation in Study I, five independent assessors viewed 
the pictures of distal colons and used a visual analog scale to estimate inflammatory 
damage. 
 
A new method for damaged area evaluation was developed for Studies II and III. The 
photographs of the distal colon were digitized using a Canoscan slide-digitizer 
(Canon Inc., Tokyo, Japan). The digitized images were then analyzed on a computer 
using the built-in properties of the commercial Corel Draw 7.0 program (Corel 
Corporation, Ottawa, Canada). The scanned pictures were split into hue-saturation-
  49
brightness channels, from which the latter was used for further evaluation. Damaged 
area was defined as that with a densitometric value below 126 (hemorrhagic, red); 
likewise, densitometric values of 126 and above (healthy, pale) designated the 
healthy area. The damaged area divided by the total area of the colon sample was 
used to score inflammatory damage. 
 
4.2.2 Myeloperoxidase activity 
Measurement of myeloperoxidase activity was carried out using a method described 
by Pfeiffer & Qiu (1995). The scraped mucosa was weighed, and homogenized in 
ice-cold potassium phosphate buffer (pH 6.0) containing 0.5% 
hexadecyltrimethylammonium bromide. The homogenates then underwent three 
freeze-thaw cycles and were centrifuged at 40,000 g for 15 minutes thereafter. The 
supernatant was then used for further analysis. An aliquot of the supernatant was 
mixed with sample buffer containing o-dianisidine and H2O2. The enzymatic reaction 
was followed with a spectrophotometer at 480 nm for 2 minutes. Linear reaction 
kinetics were obtained by dilution of sample. The change in absorbance in one 
minute is directly proportional to the myeloperoxidase activity of the sample. One unit 
of activity was defined as that degrading 1 µmol of hydrogen peroxide in one minute. 
 
4.2.3 Prostaglandin E2 metabolite in plasma 
The measurement of a metabolite of PGE2, 13,14-dihydro-15-keto-prostaglandin-E2 
(PGEM), was carried out by radioimmunoassay as described by Mucha and 
Losonczy (1990).  
 
4.2.4 Nitrate and nitrite in plasma 
Nitrate and nitrate were measured using a modified Griess reaction (Green et al., 
1982). Proteins were precipitated in diluted serum samples with ZnSO4. Since the 
Griess reaction detects only nitrite, nitrate was reduced to nitrite enzymatically by 
adding nitrate reductase and cofactors (Moshage et al., 1995).  
 
4.2.5 Nitric oxide synthase activity 
Nitric oxide synthase activity was assessed by measuring the conversion of 
[14C]arginine into [14C]citrulline as described by Salter et al. (1991) and Moilanen et 
al. (1998). Ice-cold 20 mM N-2-hydroxyethylpiperazine-N’-2-ethane-sulfonic acid 
buffer (pH 7.2) containing 200 mM sucrose, 0.1 mM ethylenediaminetetraacetate, 5 
mM dithiothreitol, 10 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor and 1 µg/ml 
pepstatin A was added to the tissue samples. Samples were homogenized on ice 
and centrifuged at 10,000 g for 30 minutes. Supernatants were treated with an equal 
volume of cation exchange resin (Dowex-50W, sodium form) to remove endogenous 
arginine. The NOS activity in the supernatants (cytosol + microsomes) were 
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measured by the conversion of L-[U-14C]arginine to L-[U-14C]citrulline at 37 oC for 10 
minutes in 20 mM N-2-hydroxyethylpiperazine-N’-2-ethane-sulfonic acid buffer (pH 
7.2) containing 10 µM tetrahydrobiopterin, 2.5 mM dithiothreitol, 400 U/ml calmodulin, 
250 µM CaCl2, 0.5 mg/ml bovine serum albumin, 125 µM reduced 
nicotineadeninedinucleotidephosphate, 10 µM arginine, 100 µM citrulline, 60 mM 
valine (to inhibit arginase) and 0.33 µCi/ml L-[U-14C]arginine. 
 
The total NOS activity was determined from the difference between the L-[U-14C]-
citrulline generated in control samples and samples containing 1 mM L-NMMA; the 
activity of the calcium-dependent NOS activity was determined from the difference 
between control samples and samples containing 1 mM of the calcium chelator, 
ethylene glycol bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetate, and the activity of 
calcium-independent NOS was determined from the difference between samples 
containing 1 mM calcium chelator and those with 1 mM L-NMMA. Protein content of 
the tissue supernatant was measured by Coomassie Brilliant Blue assay (Bio-Rad, 
Hercules, CA, USA) using bovine albumin as a standard. 
 
4.2.6 Western Blot 
The expression of iNOS and COX-2 proteins in rat colon and colon mucosa from UC-
patients was measured by Western Blot as described by Kosonen et al. (1998). 
Colon samples were weighed and 6 ml per mg of sample of ice-cold extraction buffer 
(10 mM Tris-base, 5 mM ethylenediaminetetraacetate, 50 mM NaCl, 1% Triton        
X-100, 0.5 mM phenylmethyl sulfonyl fluoride, 2 mM Na-orthovanadate, 10 µg/ml 
leupeptin, 25 µg/ml aprotinin, 1.25 mM NaF, 1 mM Na-pyrophosphate, 10 mM          
n-octyl-β-D-glucopyranoside) was added. Samples were homogenized using an Ultra 
Turrax T25 homogenizer (Janke & Kunkel GmbH, Staufen, Germany). Following 
extraction samples were centrifuged and the resulting supernatant boiled for              
5 minutes in sample buffer (62.5 mM Tris-HCl, 10% glycerol, 2% SDS, 0.025% 
bromophenol blue, and 5% 2-mercaptoethanol) and stored at -20 °C until analyzed. 
An aliquot of supernatant was used to determine protein by the Coomassie blue 
method (Bradford, 1976). Protein samples (20 µg) were separated by electrophoresis 
on polyacrylamide gel and were transferred to a nitrocellulose membrane. The 
desired proteins were detected using specific primary antibodies and their respective 
horseradish peroxidase conjugated secondary antibodies using the enhanced 
chemiluminescence technique. The primary antibodies were: iNOS rabbit polyclonal 
antibody (M-19) and COX-2 goat poyclonal antibody (N-20) from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA), nitrityrosine rabbit polyclonal antibody from 
Upstate Biotechnology (Lake Placid, NY, USA). 
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4.2.7 Reverse transcriptase-polymerase chain reaction 
Colon samples (approximately 30 mg) were frozen and homogenized. The samples 
were lysed and purified using QIAshredderTM (QIAGEN Inc., Santa Clarita, CA, USA). 
Thereafter RNA was extracted using RNeasy kit for isolation of total RNA (Qiagen 
Inc., Santa Clarita, CA, USA). Synthesis of cDNA from mRNA and subsequent 
amplification of cDNA by PCR was performed with GeneAmp Thermostable rTth 
Reverse Transcriptase RNA PCR Kit (Perkin-Elmer; Roche Molecular Systems Inc., 
Branchburg, NJ, USA). First strand cDNA was synthesised using sequence specific 
downstream primer for rat iNOS or rat glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), which was used as reference. The upstream primer was added into the 
reaction mixture at the beginning of PCR amplification. PCR conditions were 
denaturation, annealing and extension at 94 °C for 1 min, 55 °C for 1 min and 72 °C 
for 1.5 min, respectively, and 25 cycles for both iNOS and GAPDH. The Mg2+ 
concentration in the reaction mixture was 1.5 mM. Primers for amplification of iNOS 
were 5’-CAAGCTGTATGTGACTCCATCGAC-3’ (sense) and 5’-AGATGAGCTCAT-
CCAGAGTGAGCTG-3’ (antisense) resulting a 346 bp product. Primers for 
amplification of GAPDH were 5’-CGGTGTCAACGGATTTGGCCGTAT-3’ (sense) and 
5’-AGCCTTCTCCATGGTGGTGAAGAC-3’ (antisense) resulting a 306 bp product. 
Products were analyzed on 1.5% agarose gel containing ethidium bromide and 
visualized in ultraviolet light. 
 
4.2.8 Enzyme linked immunosorbent assay 
The concentrations of IL-1β, IL-6 and TNF-α in incubation medium were analysed by 
enzyme linked immunosorbent assay (ELISA) using reagents from the Central 
Laboratory of the Netherlands Red Cross (CLB). IL-1Ra was analyzed by ELISA 
using reagents from R&D Systems, USA (Quantikine). 
 
4.2.9 Immunohistochemistry 
Mucosal samples were embedded in Tissue Tek O. C. T.  Compound (Sakura 
Finetek Inc., Zoeterwoude, Netherlands). Cryostat sections were air dried, and fixed 
in ice cold methanol. Endogenous peroxidase activity was quenched with subsequent 
incubation in PBS containing 0.3% hydrogen peroxide. The sections were then 
washed three times with ice cold PBS, incubated in normal blocking serum, washed 
and incubated overnight with the primary antibody. Thereafter the sections were 
washed and incubated with the secondary antibody. The Vectastain ABC Elite-kit 
(Vector Laboratories, Burlingame, CA, USA) was used for staining the sections. 
Monoclonal anti-iNOS (Transduction Laboratories, Franklin Lakes, NJ, USA) and 
polyclonal anti-nitrotyrosine (Upstate Biotechnology, Lake Placid, NY, USA) were 
used as primary antibodies. Respective non-immune serum was used instead of 
primary or secondary antibody as negative controls. Rabbit/mouse IgG of the same 
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subtype as the primary antibodies but with an irrelevant specificity was used as an 
additional negative control. The sections were counterstained with hematoxylin. 
 
4.2.10 Ethics 
Studies I-III were approved by the Animal Experimentation Committee of the Institute 
of Biomedicine, University of Helsinki, Finland. Study IV was approved by the Ethics 
Committee of Helsinki University Central Hospital, Second Department of Surgery, 
Helsinki, Finland. 
 
4.2.11 Statistical analysis 
Statistical analysis was carried out by analysis of variance (ANOVA) followed by 
Bonferroni multiple comparisons test. P values of <0.05 were considered significant. 
 
4.2.12  Drugs 
The drugs used in Studies II-IV are shown in Figures 4 and 5. In Study II a 
preferential inhibitor of COX-2 over COX-1, nimesulide, a non-selective COX-
inhibitor, indomethacin, and a preferential COX-1 over COX-2 inhibitor acetylsalicylic 
acid were used. In this study a corticosteroid, dexamethasone, served as control. In 
Studies III-IV a non-selective NOS-inhibitor, L-NAME, and a selective iNOS-inhibitor, 
1400W were used. In Study IV also an NO-donor, SNAP, was used. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Structures of the test drugs in Study II. a) Acetylsalicylic acid,                      
b) indomethacin, c) nimesulide, and d) dexamethasone. 
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Figure 5. Structures of the test drugs in Studies III and IV. The nitric oxide synthase 
inhibitors a) N-[3-(aminomethyl)benzyl]acetamidine, 1400W and b) NG-nitro-L-
arginine methyl esther, L-NAME, and the nitric oxide donor c) S-nitroso-N-acetyl-
penicillamine, SNAP. 
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5 SUMMARY OF RESULTS 
 
The results of the Studies (I-IV) are collectively represented in Table 13.  
 
5.1 TNBS-induced colitis (I-III) 
5.1.1 Induction of iNOS and COX-2 (I-III) 
A model of 2,4,6-trinitrobenzenesulfonic acid (TNBS) -induced acute colitis in the rat 
was characterized in Study I. TNBS induced severe macroscopic inflammation in the 
colon as early as 6 hours after induction attaining a sustained peak level at 24 hours. 
Infiltration of neutrophil granulocytes was measured as myeloperoxidase (MPO) 
acitivity. Neutrophil infiltration into the inflamed colon mucosa was enhanced at        
6-24 hours after TNBS and returned to the pre-treatment levels in 48 hours. Both 
macroscopic inflammation and inflammatory cell infiltration were associated with 
increased inflammatory edema that showed a sustained elevation similar to 
macroscopic lesions. These increases were coupled to increases in PGE2 
production, which was measured as plasma concentrations of its stable metabolite 
13,14-dihydro-15-keto-PGE2, PGEM. At 6 to 24 hours from the induction of colitis 
elevated plasma PGEM concentrations were found (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Time dependency of the activities of COX-2 and iNOS measured as 
plasma concentrations of a metabolite of prostaglandin E2 and by the iNOS-activity 
assay, respectively. 
COX-2, cyclooxygenase-2; iNOS, inducible nitric oxide synthase 
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The activity of the nitric oxide producing inducible enzyme, iNOS, showed a more 
sustained, but delayed onset response as compared to the production of PGE2 
(Figure 6). In order to compare the systemic and local inflammatory responses, iNOS 
activity was measured also in the spleen (a homing site for lymphocytes). A very low 
activation of iNOS as compared with local iNOS activation in the distal colon was 
seen in the spleen suggesting that the TNBS-insult produces a local rather than a 
systemic acute response, at least in the sense of nitric oxide production. This effect 
was also demonstrated in plasma nitrite and nitrate concentrations that remained 
unchanged throughout the study period. The study also identified neutrophil infitration 
and prostaglandin E2 production as transient responses, while iNOS activity, 
macroscopic inflammation, and inflammatory tissue edema showed a more sustained 
course during the 72 hour study period.  
 
5.1.2 Inhibition of cyclooxygenase (II) 
The expression of the inducible cyclooxygenase, COX-2 was found to be increased 
in the distal colon at  6 to 24 hours after induction of colitis with TNBS. The time 
course of COX-2 protein expression was consistent with the previously measured 
plasma concentrations of PGEM. A novel method was introduced to measure the 
ratio of damaged to total mucosa instead of the previous more subjective evaluation 
by independent assessors that was used in Study I. The chemical composition of 
drugs used in Study II are shown in Figure 4. 
 
Treatment with a preferentially COX-2 over COX-1 inhibiting NSAID, nimesulide, 
suppressed the increase in plasma PGEM, decreased formation of inflammatory 
edema and reduced infiltration of neutrophil granulocytes into the inflamed colon 
mucosa. Nimesulide inhibited COX-2 levels in the distal colon mucosa. Because 
nimesulide failed to down-regulate COX-2 expression in murine macrophages in cell 
culture, we concluded that its in vivo effect is due to reduced inflammatory area in the 
distal colon. However, nimesulide failed to show inhibitory action in macroscopic 
lesions in the gut as measured by the computerized method. 
 
The anti-inflammatory actions of nimesulide in this model were compared to two 
other NSAIDs: to  a relatively COX-1 selective inhibitor, acetylsalicylic acid (ASA), 
and to a non-selective COX –inhibitor, indomethacin. Indomethacin inhibited COX-2 
activity (as measured by plasma PGEM concentrations) and the formation of 
inflammatory edema, but failed to suppress infiltration of neutrophil granulocytes or 
macroscopic damage. Treatment with ASA did not have any effects on these 
parameters measured. In this model, the actions of nimesulide were similar to those 
of dexamethasone treatment. The anti-inflammatory, synthetic glucocorticoid, 
dexamethasone exerts its effects via different mechanisms of action including 
suppression of COX-2 expression (as shown in Study II with J774 macrophages) and 
thereby reduces the formation of prostaglandins. 
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5.1.3 Inhibition of nitric oxide synthase (III) 
The model of TNBS-induced acute colitis in the rat was evaluated in respect to the 
expression of iNOS. In Study I it was reported that in this model a local increase in 
iNOS activity is present. The time dependence of iNOS expression was 
demonstrated at mRNA and protein levels in the distal colon after TNBS enema. A 
marked increase in iNOS protein and mRNA expression was already found 6 hours 
after induction. Expression of iNOS mRNA declined to the baseline levels after 24 
hours, and also iNOS protein levels decreased to some extent. However, in concert 
with previously reported iNOS activity there was still a significantly increased amount 
of iNOS protein present at the inflammatory focus at 72 hours after TNBS enema. 
The drugs used in this study are shown in Figure 5. 
 
In the 24-hour acute model of colitis, subcutaneous administration of a highly 
selective iNOS inhibitor, N-[3-(aminomethyl)benzyl]acetamidine (1400W) attenuated 
the infiltration of inflammatory neutrophil granulocytes, inhibited the formation of 
inflammatory edema and prevented development of macroscopic ulcerative damage. 
Treatment of colitis with a preferential inhibitor of constitutive NOS, N-nitro-              
L-arginine-methyl-esther (L-NAME) showed no effects in this model. As found in   
Study I, no increases were seen in plasma nitrite and nitrate –concentrations after 
induction of colitis TNBS-enema. Thus the effectiveness of the studied drugs could 
not be evaluated by measuring the concentrations of these NO-metabolites in    
Study III. 
 
5.2 Selective inhibition of mucosal iNOS in ulcerative colitis  (IV) 
The beneficial effect with selective inhibition of iNOS was further evaluated in human 
colon mucosal tissue from patients with active colitis. Tissue samples from seven 
patients undergoing elective proctocolectomy at the Helsinki University Central 
Hospital, II Department of Surgery, were obtained for the experiments. Uninflamed 
mucosal tissue from the same patient’s colon served as a control.  
 
The expression of iNOS protein was first determined in these samples using Western 
Blot. In inflamed mucosa a tenfold increase in iNOS expression was found as 
compared to uninflamed tissue samples. Using immunohistochemistry on samples 
from two patients, the expression of iNOS was localized to cells in the lamina propria. 
In some areas immunopositive staining was seen also in the apical microvillous 
border of epithelial cells. As reported in the literature iNOS activity in inflammation is 
coupled to the formation of reactive nitrogen species (RNS) (Coleman, 2001). iNOS-
derived NO rapidly reacts with tissue superoxide to form the cytotoxic peroxynitrite 
anion. In Study IV nitrotyrosine was used as a marker of peroxynitrite formation, even 
though some nitrotyrosine is also formed in physiological processes unrelated to 
peroxynitrite. The total expression of nitrotyrosine showed an increasing tendency, 
and the expression of a tyrosine nitrated 25kDa protein was significantly enhanced in 
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the inflamed tissue. Expression of nitrotyrosine was co-localized with iNOS in cells of 
the lamina propria.  
 
The effects of the iNOS inhibitor, 1400W were compared to those of a cNOS 
inhibitor, L-NAME and those of an NO-donor, S-nitroso-N-acetyl-penicillamine 
(SNAP). Both the inflamed and uninflamed mucosa was incubated in tissue culture 
for five hours in the absence or presence of the drugs studied. The accumulation of 
pro-inflammatory cytokines IL-1β, IL-6, and TNF-α and of the anti-inflammatory 
cytokine IL-1Ra in the culture medium was quantitated. Both the inflamed and 
uninflamed mucosa produced detectable amounts of the proinflammatory cytokines, 
but the levels of nitrite, a stable end-product of NO metabolism, were undetectable. 
 
In the inflamed mucosa, selective inhibition of iNOS with 1400W inhibited the 
accumulation of TNF-α and IL-6, while cNOS inhibition with L-NAME was ineffective. 
Supplementation of exogenous NO by SNAP produced significant increases in pro-
inflammatory cytokine accumulation. As further evidence of a pro-inflammatory effect 
of exogenous NO in the inflamed mucosa, the concentrations of the anti-inflammatory 
cytokine IL-1Ra were inhibited with SNAP treatment. In the uninflamed mucosa, 
selective iNOS inhibition reduced the release of TNF-α, whereas inhibition of cNOS 
had no effect on pro-inflammatory cytokine concentrations. Treatment of the 
uninflamed mucosal samples with the NO-donor, SNAP, decreased the levels of IL-6 
thus evidencing a dual role for NO depending on the activity of inflammation. 
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6 DISCUSSION 
 
6.1 Methodological considerations 
6.1.1 TNBS-induced experimental rat colitis 
The TNBS-model of colitis is a widely used experimental animal model of human 
IBD. It features several important pathogenetic characteristics of these chronic 
relapsing diseases. The TNBS-model was set up for the present experiments based 
on the literature stating its usefulness for pharmacological studies. In the beginning, 
the acute model was characterized for iNOS and COX-2 expression and other 
parameters of inflammation needed later on in the experiments. The dose of TNBS 
needs to be adjusted for the rat strain used and the time course of inflammation 
should be evaluated before starting work with this model. Even though the TNBS 
model of experimental colitis is technically easy to perform, a highly routined inductee 
is required for reproducible results. For example, it is not uncommon that a fecal 
concrement blocks catheter entry and even distribution of TNBS in the colon leading 
to an unevenly localized inflammatory response. Fasting the rats, on the other hand 
may result in a less severe inflammation and increase aggression in animals. To 
avoid these problems in the Studies I-III the same person always routinely iduced 
colitis. 
 
In Studies II and III only a piece from the distal colon was taken as a sample for 
measuring COX-2 or iNOS activity or expression. During interpretation of the results, 
however, it was found out that the whole distal colon mucosa should be sampled, not 
just merely one piece. Since the whole mucosa of the distal colon was scraped for 
the measurement of MPO-activity, these results more adequately represent the state 
of the distal colon, only 1.5 cm of the distal part was excluded. However for studying 
iNOS activity (Study I), COX-2 protein expression (Study II) and iNOS mRNA and 
protein expression (Study III) only samples from the distal colon were used. In these 
studies care was taken to ascertain even distribution of TNBS in the colon by slowly 
pulling the catheter outwards when injecting TNBS.  
 
The present model of TNBS-induced colitis is characterized by the general features 
of acute inflammation, and thus provides information on common acute inflammatory 
mechanisms of the gut rather than on any specific disease. As compared to vehicle 
treatment, administration of TNBS induces a more severe and sustained 
inflammation associated with concomitant activation of nitric oxide and prostaglandin 
production. This acute model is suited to studying preventive effects of drugs while 
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the delayed, chronic model is better adapted for studies on healing or resolution of 
inflammation.  
  
After the acute 24-48 hour phase, TNBS-colitis develops into a chronic phase that 
lasts up to eight weeks (depending on the animal and strain)(Morris et al., 1989). This 
chronic phase is characterized by activation of the immune system and cell mediated 
adaptive immunity (Wirtz and Neurath, 2000). It is also associated with increased 
mucosal infiltration of T-helper lymphocytes and production of cytokines (e.g. IFN-γ, 
TNF-α, IL-2 and IL-12) (Strober et al., 1998; Sun et al., 2001). The chronic stage has 
distinct similarities with human CD: transmural lesions, formation of granulomas, and 
the overall cytokine profile (Morris et al., 1989). An interesting feature of TNBS-colitis 
is that it can be reactivated by intravenous injections of TNBS suggesting a delayed 
hypersensitivity reaction (Appleyard and Wallace, 1995). 
 
The TNBS model of colitis has many attractive features for studying human IBD. 
However, many beneficial drug effects initially found by using this model have turned 
out to be ineffective in subsequent clinical studies. Thus, the model can only provide 
a basis for preliminary testing and direction for drug development. The method of 
induction is easy, but quite ingenious in its principle in initiating disease by mimicking 
and utilizing known factors (e.g. the role of bacteria, epithelial damage and 
dysfunction, and immune activation) of IBD pathogenesis. It is a well characterized 
animal model, and as such the obtained results are to be considered to be reliable. 
 
6.1.2 Incubation of colitic mucosa 
Material for Study IV was obtained from patients undergoing elective 
proctocolectomy. These patients had previously been diagnosed with UC. All patients 
were treated with oral steroids. The resected bowel might have suffered from 
ischemia during its surgical removal. Nevertheless, reperfusion injury was avoided 
since the tissue was removed from the body.   
 
Prior to incubation the mucosal samples were quickly transferred to the laboratory in 
ice-cold saline and were washed. In incubation, no external stimulus was added, only 
the spontaneous release of inflammatory mediators was assessed in the presence or 
absence of drugs. When it is being incubated the mucosal sample is of course 
without blood supply, but this setup permits study with experimental drugs on human 
tissues, and in human disease relevant to therapy. The results obtained are to be 
considered as a total sum of the interplay of all the mediators and cellular 
components. The patients were on steroid treatment that has various anti-
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inflammatory actions at cellular level. Their other medications may also play some 
role in the results obtained from this particular setup.  
 
In conclusion, in vitro incubation of colon tissue derived from patients with UC is a 
simple method that utilizes inflamed human tissue in pharmacological studies on 
novel treatment approaches for inflammatory bowel disease with experimental drugs.   
 
6.2 Factors contributing to induction of iNOS and COX-2 in TNBS-
colitis 
The two components in the TNBS-solution, 2,4,6-trinitrobenzenesulfonic acid and 
ethanol both contribute to tissue injury in colitis. As evidenced in Study I, treatment 
with ethanol alone induces a less severe inflammatory response associated with low 
iNOS activity as compared to the lesions caused by its combination with TNBS. The 
TNBS-induced damage and iNOS activation lasted throughout the study period 
although some resolution was evident at 72 hours. The acute effect of TNBS and the 
lesser action of ethanol alone suggest that increased iNOS activity is a non-specific 
response to acute tissue injury and is related to the severity of the inflammatory 
response. Furthermore, these TNBS-induced changes were in direct correlation with 
the formation of inflammatory edema.  
 
Activation of COX-2 in this model was evaluated by measuring plasma 
concentrations of a stable metabolite of PGE2, PGEM. Plasma PGEM increased 
concomitantly with mucosal MPO-activity, a measure of neutrophil granulocyte 
infiltration. Both significantly increased for 6-12 hours and declined to almost their 
baseline levels 48 to 72 hours after induction of colitis. As found in Study II, also 
COX-2 expression showed a similar time-course. These results suggest that COX-2–
derived PGE2 contributes to the acute phase of inflammation (ad 24 hours) 
characterized by neutrophil infiltration, but is not as important thereafter in the 
perpetuation of inflammatory damage. 
 
TNBS has been reported to induce cell lysis, increase oxidative and nitrosative 
stress, modify cell surface proteins, and initiate immunologic activation (see 2.5.1). 
These factors contribute to the prolonged and accentuated effects seen after 
induction of colitis with TNBS. After the inflammatory insult and cell damage, the 
body responds with activation of the acute inflammation cascade. In active 
inflammation cell destruction and increased permeability allow bacteria to enter the 
lamina propria. Pro-inflammatory cytokines and bacterial antigens induce and drive 
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the transcription of both COX-2 and iNOS. In the 24 hour acute model of TNBS-colitis 
increased levels of IL-1β, IL-6, and TNF-α have been reported (Sun et al., 2001). 
These cytokines exert their activities through activation of the transcription factor NF-
kappaB, which also has been shown to be induced in experimental (Neurath et al., 
1996) and IBD-colitis (Schreiber et al., 1998). 
 
In the acute TNBS-induced model of colitis induction of iNOS and COX-2 occurs in 
response to cellular injury and immune activation. After a rapid induction of COX-2 
expression and activity associated with neutrophil granulocyte infiltration, a more 
persistent induction of iNOS expression and activity is seen that correlates well with 
macroscopic inflammation. These results are in concert with earlier published 
observations on human inflammatory bowel disease (Hendel and Nielsen, 1997; 
Kimura et al., 1997) suggesting a further verification of the model in studying the 
roles of iNOS and COX-2 in gut inflammation. 
 
Inflammation increases intestinal permeability and may thereby permit bacteria or 
bacterial antigens to enter the lamina propria and systemic circulation (Neilly et al., 
1995). This low-grade endotoxemia may explain the induction of splenic iNOS activity 
as found in Study I. TNBS-induced colitis has not been associated with hepatobiliary 
abnormalities even though they are quite frequently found in human disease 
especially in UC (Hendrickson et al., 2002). In experimental models of IBD, various 
changes in sites unaffected by the initial insult have been reported. Some studies 
have reported alterations and disturbances in myoelectric activity and adrenergic 
nerve function in both the inflamed and the uninflamed colon (Jacobson et al., 1997) 
and in the uninflamed ileum (Aube et al., 1999). Also alterations in the expression of 
electrolyte transporter proteins in the uninflamed ileum have been found (Khan and 
Ali, 1999). 
 
6.3 Effects of COX-2 inhibition in colitis 
As found in Study II the expression of COX-2 was increased and was associated with 
inflammatory edema and neutrophil infiltration into the inflamed colon, and with 
plasma PGEM concentrations. However, even if marked suppression in these 
parameters was attained with preferential COX-2 inhibition (nimesulide, and also 
dexamethasone) and with non-selective COX-1/-2 inhibition (indomethacin) no 
beneficial effect was found in evaluation of macroscopic damage of the inflamed 
colon.  
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A relatively low dose of ASA (10 mg/kg) was used in this study in order to inhibit only 
COX-1, and failed to provide anti-inflammatory benefit. Since prostaglandin 
production in this model was associated with COX-2 expression and activity, the lack 
of effect on COX-2 by ASA may explain its poor anti-inflammatory action. 
Deacetylation or decomposition of ASA was not evaluated, but the salicylate 
concentrations formed were most likely too low to cause any significant inhibition of 
COX-2. 
 
In the literature, the general assumption of a straightforward detrimental role for 
COX-2 activity and prostaglandin production has been challenged in colitis (Felder et 
al., 2000). There are reports of acute exacerbations of IBD in patients treated with 
inhibitors of COX (Kaufmann and Taubin, 1987; Aabakken and Osnes, 1989). The 
NSAIDs have also been associated with colitis in otherwise healthy individuals 
(Faucheron and Parc, 1996). Selective inhibitors of COX-2 as well as conventional 
NSAIDs have been reported to aggravate inflammation or show no beneficial effect in 
some experimental models of IBD (Table 12). Recent studies have identified an anti-
inflammatory role for COX-2 derived prostaglandins and PGD2 as the major anti-
inflammatory prostaglandin that is produced through this pathway (see 2.5.3). On the 
other hand, there are a number of studies showing a beneficial effect on colitis by 
NSAIDs of various selectivities towards COX-2 (Tardieu et al., 2000; Cuzzocrea et 
al., 2001b). The favorable effects of these drugs can also be attributed to their COX-2 
unrelated actions. 
 
6.4 Effects of iNOS inhibition in colitis 
In Study III, a beneficial effect of selective iNOS inhibition on experimental TNBS-
induced colitis was found. This finding is in concert with previous observations using 
relatively less iNOS selective agents, which also have additional mechanisms of 
action besides iNOS inhibition (see 2.2.1). Thus it is proposed that in acute 
inflammation of the gut iNOS activity has a pro-inflammatory action. The same highly 
selective iNOS inhibitor was concomitantly used in a more chronic model of colitis, 
and also showed beneficial effects on inflammation in that model (Menchen et al., 
2001).  
 
Since iNOS is preferentially expressed in areas of inflammation, it presents a highly 
focused approach to treating inflammation. Even in IBD patients treated with 
glucocorticosteroids, there is sustained expression of  iNOS associated with 
macroscopic inflammation (Leonard et al., 1998). In patients, whose disease is still 
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uncontrolled receiving steroid therapy, selective iNOS inhibitors may provide 
additional benefits. 
 
Analogous to prostanoids, NO may also have anti-infammatory effects. This is 
demonstrated by the findings that iNOS deficient mice are susceptible to more severe 
inflammatory damage induced with TNBS enema than their wild type littermates 
(McCafferty et al., 1997), and IL-10/iNOS –double deficient mice develop 
spontaneous colitis (McCafferty et al., 1999). In these studies iNOS deficiency does 
not provide additional protection from colitis as would be expected if iNOS activity 
was totally pro-inflammatory. In light of these results, NO has anti-inflammatory 
actions, but high concentrations of iNOS-derived NO and its oxidative, toxic 
metabolites augment the inflammatory response (Zingarelli et al., 1999b; Hokari et 
al., 2001).  
 
6.5 Interplay of prostaglandins and nitric oxide in colitis 
It has been unambiguously shown in vitro that there are complex interplay and 
feedback mechanisms between prostaglandin production and nitric oxide synthesis. 
NO has been shown to activate COX enzymes (Salvemini et al., 1993; Maccarrone et 
al., 1997) and prostaglandins (PGE-analogs) have been shown to activate NOS 
(Dieter et al., 1999). In Study I, the time-courses of iNOS activity and plasma PGEM 
suggest that since the increase in PGE2 is more acute, it may drive the activation of 
NOS in this model. iNOS activity remained at a relatively high level, but PGEM 
concentrations had a more transient course demonstrating that iNOS-derived NO 
production is not capable of maintaining PGE2 production or that PGE2 is derived 
from infiltrating inflammatory cells and that NO inhibits this infiltration.  
 
NO has been shown to inhibit the COX-enzymes representing an additional 
mechanism for NO’s anti-inflammatory effects (Swierkosz et al., 1995; Tanaka et al., 
2001). However, as some prostaglandins have protective effects on the 
gastrointestinal mucosa, inhibition of their production by NO may increase 
inflammatory damage. On the other hand, in other models NO activates COX-
enzymes and increases production of prostaglandins (Salvemini et al., 1993; 
Goodwin et al., 1999; Devaux et al., 2001). Peroxynitrite has been shown to increase 
and activate the cyclooxygenase activity of COX-enzymes in vitro (Goodwin et al., 
1999). It may serve as a substrate for the enzyme’s peroxidase activity leading to 
enhanced production of prostaglandin endoperoxides (PGG2 and PGH2) (Landino et 
al., 1996) demonstrating a physiological rather than toxic effector function for 
peroxynitrite.  
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Prostagladins E2 and J2 have been shown to inhibit NOS activity and expression in 
different experimental setups (Harbrecht et al., 1997; D'Acquisto et al., 1998). Also 
overexpression of COX-2 in intestinal epithelial cells inhibits iNOS induction in 
response to pro-inflammatory cytokines (Kobayashi et al., 2001). In contrast, 
inhibition of COX-activity reduces iNOS expression and activity in murine 
macrophages (Aeberhard et al., 1995; Posadas et al., 2000) demonstrating NOS-
activation by prostaglandins. Furthermore, PGE2 increases LPS-stimulated NO 
production (Dieter et al., 1999) and enhances NF-kappaB activity (Poligone and 
Baldwin, 2001). The exact mechanism and relevance of these modulations remain to 
be elucidated and seem to exhibit significant variation depending on the experimental 
setup (Weinberg, 2000). From Study I it is concluded that the increased production of 
PGE2 preceding the induction of iNOS activity suggests activation of NOS by 
prostaglandins in vivo. The increased NO produced by induced iNOS activity 
subsequently inhibits COX and PGE2 production as measured in plasma as PGEM. 
 
Since the expression and activity of both iNOS and COX-2 is induced by the same 
pro-inflammatory agents and is associated with inflammatory conditions, it has been 
proposed that inhibition of both iNOS and COX-2 would provide the most potent anti-
inflammatory effect (Weinberg, 2000). 
 
6.6 Selective inhibition of iNOS in ulcerative colitis mucosa  
Study IV concentrated on the anti-cytokine activities of selective iNOS inhibition and 
showed that inhibition of iNOS activity in UC may beneficially modulate the pro-
inflammatory cytokine profile in both inflamed and uninflamed colon mucosa.  
 
NO has both anti-inflammatory and pro-inflammatory effects. The latter is mainly due 
to the detrimental oxidative metabolism of NO in inflammation while the former is 
mediated via specific intracellular pathways, namely the formation of cGMP and 
direct feedback inhibition of enzyme activity or transcription factor activation (see 
below).  As a radical species, NO reacts with other free radicals and thus exerts anti-
inflammatory radical quenching activity. However, under oxidative stress as 
frequently found in inflammation other nitrogen oxides such as N2O3, and 
peroxynitrite anion are rapidly formed from NO. This detrimental metabolism of NO 
can be limited through selective inhibition of iNOS, which in addition to producing 
high concentrations of NO has been shown to produce superoxide and to contribute 
to oxidative stress (see 2.2).  
 
Expression of iNOS and 3-nitrotyrosine co-localized to cells in the lamina propria. 
Incubation of inflamed mucosa with a highly selective iNOS inhibitor decreased pro-
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inflammatory cytokine release and synthesis supporting the hypothesis that in active 
inflammation iNOS activity is detrimental. The NO-donor, SNAP increased the 
release of IL-1β, IL-6, and TNF-α. The results suggest that both iNOS-derived and 
exogenous NO may have pro-inflammatory effects in UC. In uninflamed tissue 
selective iNOS inhibition suppressed the release of TNF-α, while SNAP decreased 
the release of IL-6 in the incubation medium. Inactive mucosa may therefore benefit 
from NO supplementation, but selective inhibition of iNOS activity also seems to 
provide some anti-inflammatory advantages in quiescent inflammation. 
 
The mechanisms underlying these effects of NO and NO-derived species on cytokine 
production in inflammation are intricate and equivocal. One of many explanations, 
which is highly attractive but hypothetical is the finding that NO and reactive oxygen 
species directly activate p21ras (Connelly et al., 2001). This G-protein in turn activates 
kinases involved in NF-kappaB activation such as the I-kappaB-kinase, which 
phoshorylates and inactivates the inhibitor of NF-kappaB activation (I-kappaB) 
(Lander et al., 1995b). Under different conditions, for example in inactive disease as 
shown in Study IV, the anti-inflammatory effects of exogenous NO are prominent. NO 
inhibits I-kappa-B and the DNA-binding of NF-kappaB; NO acts as an antioxidant and 
quenches reactive oxygen species thereby limiting their p21ras-activating potential 
and NF-kappaB driven cytokine synthesis (Figure 7). 
 
In Study IV, a beneficial effect was seen on the accumulation of TNF-α with the 
selective inhibitor of iNOS, 1400W. This result agrees with previous findings, where 
another selective iNOS inhibitor, ITU, was reported to inhibit TNF-α release from rat 
peritoneal macrophages (Southey et al., 1997). This pro-inflammatory effect of NO 
may be mediated through increased cGMP since NO enhances TNF-α release form 
monocyte macrophages and neutrophils by an effect mimicked by cyclic GMP (Gong 
et al., 1990; Eigler et al., 1993; Van Dervort et al., 1994; Deakin et al., 1995; 
Marcinkiewicz et al., 1995) and associated with a decrease in cAMP (Wang et al., 
1997).  
 
Interactions between cytokines modulate their own release and that of each other. 
TNF-α increases its own and IL-6 release, the effects seen in inflamed mucosa 
treated with the NO-donor (enhanced release of both mediators) or iNOS 
(suppression of release of both cytokines) may be partly explained by this 
mechanism (Strong et al., 1998).  
 
The inhibitory effect of NO on IL-6 production as observed in uninflamed mucosa 
after treatment with the NO-donor SNAP in Study IV has also been found in murine 
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macrophages (Deakin et al., 1995) and enterocytes (Meyer et al., 1995), and also in 
human chondrocytes (Henrotin et al., 1998). However, the exact mechanism behind 
this downregulation is unclear. It has been shown that NO through S-nitrosylation 
inhibits the c-jun N-terminal kinase, which in human monocytes has been shown to 
increase IL-6 release (Tuyt et al., 1999). In the uninflamed mucosa of Study IV, the 
effects of exogenous NO may be mediated through similar mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Biphasic regulation of inflammation by nitric oxide (Connelly et al., 2001).  
COX-2, cyclooxygenase-2; I-kappaB, inhibitor of NF-kappaB; iNOS, inducible nitric oxide synthase; 
NF-kappa-B, nuclear factor kappaB; NO, nitric oxide; ONOO-, peroxynitrite anion; p21ras, a G-protein; 
PGE2, prostaglandin E2; ROS, reactive oxygen species; TNF-α; tumor necrosis factor alpha. See 
below for an explanation of the letters. 
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Explanation of the letters in Figre 7. 
A  Nitric oxide rapidly reacts with the superoxide anion to produce peroxynitrite anion (Pryor 
and Squadrito, 1995). Peroxynitrite has been shown to activate the oxygen sensing        
G-protein p21ras (Spear et al., 1998)  
 
B NO reacts directly with the oxygen sensing, p21ras
 
and modifies this protein rendering it 
constitutively active thereby exerting an NF-kappaB activating cascade (Lander et al., 
1995a) 
 
C NO as a radical reacts with e.g. lipid peroxides and reactive oxygen species. This has 
been proposed as the anti-oxidative effect of NO. Thus NO quenches ROS, which act as 
activators of p21ras (Lander et al., 1995b) 
 
D High concentrations of NO inhibit the activation of I-kappaB kinase (IKK), an inhibitor of    
I-kappaB’s NF-kappaB inhibiting activity. Active IKK phosphorylates I-kappaB leading to 
release of I-kappaB from the NF-kappaB dimer and subsequent activation of NF-kappaB 
(Umansky et al., 1998). By this mechanism NO inhibits NF-kappaB activation 
 
E NO induces and stabilizes I-kappaB (Peng et al., 1995) and thus enhances its inhibitory 
effect on NF-kappaB. I-kappaB is an inhibitor of NF-kappaB activity, and is associated 
with the NF-kappaB dimer preventing its translocation and transcriptional activity (Baldwin, 
Jr., 1996) 
 
F NO has been shown to directly nitrosylate cysteine 62 in the p50-subunit of NF-kappaB 
dimer. This nitrosylation results in inhibition of NF-kappaB DNA-binding activity (Matthews 
et al., 1996) 
 
G and H Conflicting results exist on the regulation of COX and NOS activites by NO and 
PGE2, respectively. This was discussed in more detail in section 6.5 
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7 SUMMARY AND CONCLUSIONS 
 
This thesis addressed the roles of the inducible enzymes, iNOS and COX-2 in colitis. 
The contribution of these enzymes to inflammation was evaluated with the use of 
pharmacologic agents having different inhibitory selectivities for the inducible and 
constitutive isoforms of NOS or COX.  
 
I TNBS-induced colitis in the rat was characterized by induction of iNOS and 
COX  activity and was associated at 24 hours after induction with increased 
macroscopic inflammation, edema, and infiltration of inflammatory cells. 
 
II Increased PGE2 formation was coupled to the local induction of COX-2 protein 
in the inflamed colon mucosa in TNBS-colitis. Inhibition of COX-2 activity or 
expression reduced inflammatory edema and neutrophil granulocyte 
infiltration, but not macroscopic inflammation in the inflamed distal colon. 
 
III The expression of iNOS was increased in the inflamed colon. Selective 
inhibition of iNOS activity reduced edema formation, neutrophil granulocyte 
infiltration, and macroscopic inflammation in the distal inflamed colon. 
 
IV The expression of iNOS was increased in the inflamed mucosa of UC as 
compared with the uninflamed control mucosa. Selective inhibition of iNOS 
suppressed the release of pro-inflammatory cytokines providing additional 
proof of a detrimental role for iNOS activity in UC. 
 
The activities of iNOS and COX-2 contributed to inflammatory cell infiltration and 
formation of edema. The macroscopic severity of inflammation was associated with 
iNOS activity, and was suppressed by selective inhibition of this enzyme. Increased 
iNOS expression was also found in the inflamed mucosa of patients with UC. 
Selective inhibition of iNOS in vitro suppressed the release of pro-inflammatory 
cytokines by the inflamed mucosa providing additional proof of a detrimental, 
inflammation promoting role for iNOS activity in these patients. 
 
These results suggest that in inflammatory bowel disease a beneficial therapeutic 
effect is to be obtained with selective inhibition of iNOS. Inhibition of iNOS is a novel 
anti-inflammatory mechanism which attacks the inflammation associated NO 
producing enzyme. In chronic diseases iNOS produces reactive nitrogen oxides that 
increase host tissue damage and contribute to perpetuation of immune activation and 
inflammation. Further studies with highly selective iNOS inhibitors are warranted. 
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